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Abstract
Allostery is the regulation of a protein by binding in an area distinct from the enzyme
active site, but despite having clear applications in biotechnology and in drug discovery,
elucidation of it’s complexities are still ongoing. Allostery can be either activating
or inhibiting and the allosteric site is often distant to the one affected. The enzyme
Psychrobacter arcticus ATP phosphoribosyl transferase (ATPPRT) is both allosterically
activated and inhibited and is therefore useful as a model organism for understanding
allostery. P. arcticus, ATPPRT is a Type IV ATPPRT, catalyzes the first step in histidine
biosynthesis, and is comprised of two subunits: a short form HisGS and HisZ. HisGS
is the catalytic domain and is allosterically activated by HisZ. HisZ, also contains an
allosteric binding site for inhibition by histidine. Short form HisGS alone is catalytically
active but insensitive to histidine. This work establishes the kinetic mechanism of
histidine inhibition in PaATPPRT, with histidine binding non-competitively with respect
to both substrates (ATP and PRPP). AMP was confirmed as an competitive inhibitor with
respect to both substrates for both PaATPPRT and PaHisGS and ADP was determined
to be an alternative substrate. This work demonstrates the first example of histidine
binding in a site analogous to that of HisRS in a short-form ATPPRT. It also highlights
an interaction between two loops in PaHisZ, mediated by a hydrogen bond between
Tyr263 and His104, that is likely to greatly reduce the probability of the complex
sampling the activated conformation necessary for successful reaction. Additionally, a
clear distinction between the activated form of PaATPPRT with ATP bound compared to
all other structures is observed. Overall, this work demonstrates a clear reliance on key
structural changes for the allosteric regulation of PaATPPRT.
Attempts to purify Staphylococcus aureus ATPPRT were unsuccessful.
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Allostery, although regarded as “the second secret of life”[1, 2], is still not completely
understood. Despite having clear applications in biotechnology [3] and in drug discovery
[4], elucidation of it’s complexities are still ongoing. There is a consensus over what
allostery is and what allostery can do, yet several details of its intricacies remain elusive.
1.1.1 Allostery: The Basics
Allostery is the regulation of a protein by binding in an area distinct from the active
site [5]. For example, Figure 1.1 shows a simple allosteric inhibitor. The allosteric
inhibitor binds to a second binding site (not the active site), which in this case, causes a
conformational change that prevents substrate binding. In theory, this means that aside
from the active site, any area inside or on the surface of the protein is a potential allosteric
effector binding site [6].
Figure 1.1: Schematic representation of an allosteric inhibitor binding in a secondary
site, distorting the active site and preventing substrate binding.
Sometimes allostery and cooperativity are used interchangeably but they are in fact
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distinct concepts, though related. Cooperativity is concerned with regulation of a
multimeric protein through change in its quaternary structure from one subunit to
the same site on another subunit [5], and therefore involves allostery. Historically,
cooperativity was also referred to as allostery, however, allostery can involve any site
(except the active site) that causes a regulatory effect elsewhere in the same molecule and
thus allostery is possible in monomeric proteins too. In other words, all cooperativity is
allosteric but not all allostery is cooperative. Allostery can also be ligand-free, such as
regulation through amino acid mutations [7] or post-translational modification [8].
Cooperativity can be either positive, where binding of a ligand to one subunit increases
the affinity of binding to another subunit (Figure 1.2, A) or negative, where binding to
one subunit decreases the affinity of binding to another subunit (Figure 1.2, B)[5].
Figure 1.2: Schematic representation of positive (A) and negative (B) cooperativity.
As the positive cooperativity ligand binds, it induces a conformational change in the
neighbouring active site that increases affinity for subsequent ligand binding. As
the negative cooperativity ligand binds, it induces a conformational change in the
neighbouring active site that decreases affinity for subsequent ligand binding.
Examples of molecules displaying positive cooperativity are oxygen towards
haemoglobin [9], mannose towards glucokinase [10] and estradiol towards the estrogen
receptor [11]. An examples of a protein with negative cooperativity is CTP synthase and
its substrate glutamine [12].
Allostery too, can produce positive or negative modulation. Allosteric activation occurs
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when binding of an allosteric ligand to any non-active site in the monomeric or
multimeric protein increases the affinity and/or activity with substrate or other ligand
in their respective active sites. Examples of allosteric activators include ribosomal
S6 kinase 2 (Rsk2) to the hormone-binding domain of estrogen receptor alpha [13]
and heterodimer formation of Trypanosoma brucei S-adenosylmethionine decarboxylase
with a catalytically dead homolog [14]. Conversely, allosteric inhibition occurs when
binding of an allosteric ligand to any non-active site in the mono- or multimeric
protein decreases the affinity and/or activity with substrate or other ligand in their
respective active sites. Examples of allosteric inhibitors include phosphoenolpyruvate
with respect to Escherichia coli (E. coli) phosphofructokinase [15] and CTP with respect to
aspartate transcarbamoylase [16–18]. Some enzymes can be both allosterically activated
and inhibited, for example, synthases such as Arabidopsis threonine synthase [19]
and ATP phosphoribosyltransferases (ATPPRT) such as Psychrobacter arcticus ATPPRT
(PaATPPRT) [20].
1.1.2 Applications of Allosteric Modulation
The ability to modulate activity without interfering directly with the active site creates
broad scope for academic and industrial applications, particularly in biotechnology and
drug discovery.
Allostery in Biotechnology
With a global shift towards sustainability and environmentally robust practises, biology-
based methodologies are becoming extremely valuable. From enhancing the quality and
quantity of crops [21], to utilising low temperatures and organic-solvent free systems
for chemical synthesis [22], biotechnology is a fast growing and lucrative sector. For
example, over 4 million tons of L-amino acids are bought globally per year [23]. Many
of these amino acids, such as L-glutamate [24] and L-histidine [25] are still produced by
laborious purification from bacterial strains.
There is a clear economic and environmental advantage to engineering enzymes and
organisms to produce desirable chemicals faster and more efficiently. Given that many
enzymes are allosterically modulated, for example by feedback inhibition [16, 26],
understanding allosteric mechanisms is of great importance to overcome and engineer
allostery as needed.
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Allostery in Drug Discovery
Allostery is not only of use to the synthetic biology and biotechnology industries, it
is also of interest to the pharmaceutical industry. Allosteric drugs, have been gaining
traction over the last 5-10 years, a trend which can be visualized by analyzing the
number of papers mentioning “allosteric drug” from 1997 to 2017 (Figure 1.3). There
is a distinct rise from 4 papers to over 300 in only two decades with numerous allosteric
drug candidates now in clinical trials [27–30].
Figure 1.3: Number of publications per year that mention “allosteric drug” [31]
Although rationally designed allosteric drugs are slowly coming into the clinic, it
is orthosteric drugs that have historically dominated the pharmaceutical industry.
Orthosteric drugs bind directly to the active site of the target and directly modulate
activity by blocking further binding at that site and inhibiting the target’s function.
This makes orthosteric drug targets relatively easy to assay given that the ligand
interacts directly with the active site and the corresponding enzyme function. However,
orthosteric drugs generally result in complete inhibition or activation of the target rather
than a tunable modulation. They are also more prone to adverse side effects in patients
as many targets have similar binding sites to other enzymes with related functions
[32]. Allosteric drugs on the other hand, have a better chance of targeting subtype
specificity and reduce off-target effects as their binding sites are less conserved than
their orthosteric counterparts. Additionally, allosteric drugs have increased flexibility to
target a site that is only open to binding during specific times in activation or signalling
[33]. Unfortunately, the current limitation for allosteric drug discovery is mainly due
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to current drug design techniques being poorly suited to reporting weaker-binding
allosteric modulators [33]. However, there are some techniques, such as fragment-based
drug design, which are more suited for weaker-binding allosteric modulators.
However, allosteric drugs have actually been on the market since the early 1900s, despite
their mode of action being unknown at the time of introduction. For example, the
barbiturate, diethyl-barbituric acid, was first prescribed [34] in 1904. It has since
been determined that barbiturates (such as phenobarbital, still prescribed as an anti-
convulsant) allosterically stimulate the inhibitory neurotransmitter γ-aminobutyric acid
(GABA) and cause an increase in the length of time the GABA channel is open [35].
Similarly, benzodiazepines introduced in the 1960s, such as Diazepam, also allosterically
regulate GABA but by increasing the frequency of GABA channel opening [36] to relieve
anxiety in patients. Interestingly, both barbiturates and benzodiazepines had been in
clinical use routinely while allostery, as a concept, was just in its infancy.
1.1.3 Brief Historical Perspective of Allostery and Cooperativity
The term of “allostery” was only coined around 50 years ago. In the 1950s, covalent
modification of enzyme activity and feedback inhibition of enzymes were discovered
[37], and in 1961 ‘allosteric sites’ was used by Jacques Monod and Francois Jacob when
describing the end-product inhibition of an enzyme where the inhibitor was not a
structural analogue of the substrate [38]. A few years later, in 1965, the first model
of cooperativity was put forward by Monod, Wyman, and Changeux and is referred to as
either the symmetry model or the MWC model [39]. However, Pauling had described a
similar phenomenon in 1935 [40] when proposing a model relating to the “Bohr effect”,
the term used ca. 1903 to explain how higher concentrations of carbon dioxide could
inversely affect oxygen’s binding affinity for haemoglobin [39]. An alternative model
was proposed by Koshland, Nemethy and Filmer [41], referred to as the sequential
model or KNF model. Both the symmetry and sequential models are limiting cases of
cooperativity. They were conceived to explain haemoglobin’s binding mechanism, and
in many cases, cooperativity is unlikely to be a clear-cut example of either model. These
models are still useful and used in active research [42], but with the caveat that lots of
intermediate cases exist. It is also important to note that in the early decades of allostery
research, ‘cooperativity’ was used interchangeably with ‘allostery’. The former is now
regarded as only one type of allostery.
Symmetry Model (MWC model)
The symmetry model (Figure 1.4) of positive cooperativity acknowledges that a
symmetrical oligomeric protein exists in equilibrium between one of two stable forms
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of free enzyme, tensed state (T) and relaxed state (R) [43]. Ligand binding to one form
displaces the equilibrium towards that form. However, the symmetry model maintains
that the multimeric protein is a symmetrical oligomer and therefore subunits in the same
oligomer have the same conformational state. All subunits will be either in the R state or
in the T state. There can be no mixture of T and R state within one protein oligomer [44].
Therefore, the symmetry model describes concerted allosteric transitions of proteins to
maintain identical subunits within a given oligomer. These allosteric transitions occur
between the free protein oligomers, are independent of ligand-binding and can only
account for positive cooperativity.
Figure 1.4: Schematic representation of the symmetry model of cooperativity. Enzyme
as a whole exists in two states, T and R, and can change freely between them. Ligand
binding displaces the equilibrium towards one state. In this example binding is preferred
for the T- state (small square binding site) over the R-state (large square binding site).
Since the T-state is favoured, ligand binding by a second ligand is more favourable after
conformational rearrangement to the T state.
Sequential Model (KNF model)
The sequential model (also referred to as the induced fit model or the KNF model),
(Figure 1.5) contrary to the symmetry model, postulates that there is only one stable form
of free enzyme in solution. It states that when a cooperative ligand binds to one subunit
of the multimeric protein, it induces a conformational change in the ligand-bound
subunit [41]. This conformational change is then able to affect a neighbouring subunit,
or subunits, making it more or less likely for a second ligand to bind in neighbouring
binding sites. This creates an asymmetrical oligomer capable of having subunits in more
than one state within the same oligomer [44]. The changing of one subunit to a high
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affinity state, for example, makes neighbouring subunits more likely to transition to
a higher affinity state due to a lowering of the energy barrier correlating to that state
transition [44]. The sequential model also holds in reverse for negative cooperativity:
binding of a molecule to one subunit causes a conformational change from high to low
binding affinity in the other subunits. This is contrary to the symmetry model which can
only account for positive cooperativity.
Figure 1.5: Schematic representation of the sequential model of cooperativity. Each
enzyme subunit can exist in two interchangeable states. Ligand binding causes a
conformation change in the neighbouring subunit. In this example, binding is preferred
for the circle state (with small square binding site) over the square state (large square
binding site). Since the circle state is favoured, ligand binding by a second ligand is more
favourable after conformational rearrangement to the circle state.
Contemporary Views on Allostery
For almost 20 years the symmetry and sequential models were the best explanation
for cooperativity (with allostery as a whole being somewhat overlooked). They still
have merit as extreme cases, but the mechanism of cooperativity and allostery without
cooperativity has moved forward. The development of X-ray structures with and without
ligands [45] lent support to structural changes occurring upon ligand binding whereas
Cooper and Dryden [46] proposed that allosteric regulation was also possible without
any major conformational change, but using a shift in protein dynamics instead [47]. It
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is likely that both are possible but structural changes are the significantly more common
mechanism for allosteric regulation due to inherent flexibility, of at least some regions,
in almost all proteins [48, 49].
Views on allostery with and without cooperativity have expanded to acknowledge the
ensemble nature of proteins [50]. Protein folding is not always an all-or-none approach
between two states. For small proteins this can be the case but for large proteins
they can exist in varying degrees of unfolding or intermediate structures between their
main conformations [51]. These conformational states, or structural ensemble, have
a high degree of conformational freedom and their energy landscape has many local
energy minima [52]. Consequently, there are many possible structural conformations
available for ligand-binding to occur. With this view, allostery can be considered
as a process whereby the flexibility in proteins creates populations of conformers
that can interconvert. The binding of a molecule initiates a redistribution of protein
conformational ensembles capable of altering the proteins interconversion possibilities
[8]. Kern et.al. [53] have elegantly shown through NMR and binding kinetics that
enzyme affinity between kinases can be a direct result of differences in conformational
equilibrium post-binding, rather than differences in the binding step specifically.
Gleevec, the first kinase inhibitor to reach the market for cancer [54], is a potent drug
used to treat chronic myeloid leukaemia. Puzzlingly, despite almost identical binding
sites in the tyrosine kinase Abl subfamily and the closely related Src kinase subfamily,
Gleevec has an affinity 3000 times stronger for Abl [55]. The difference in affinity is
not due to amino acid differences in the drug binding pocket, or to a steric clash in a
highly conserved loop of Src, absent in Ab1 [55]. It was instead shown that the drastic
difference in binding affinities was due to conformational selection before binding and an
induced fit step after binding. Gleevec binds to a conformation sampled in solution much
more frequently by Ab1 than Src. Subsequent to the conformational change, there is no
noticeable difference between the two crystal structures as the binding site is identical
after the induced fit occurs and under crystallographic conditions [53]. Thus, it is the
significant equilibrium difference stemming from the ensemble nature of proteins that
distinguishes Abl from Src in Gleevec binding. The consequences of this experiment,
and others [56, 57], is an understanding that the simplistic symmetry and sequential
models that assume proteins in their native state are only in equilibrium between
stable and discrete conformations does not represent the full picture. It is now widely
accepted that proteins are continuously sampling among multiple conformations across
a complex energy landscape, with unfolding and refolding simultaneously occurring
in localized areas [8]. These redistributions include those brought into fruition by
allosteric effector binding and it is common in proteins that some states will exchange
very quickly but other conformations will take much longer to be sampled because the
barrier for the transition is much higher. However, the limiting cases of the symmetry
and sequential models for cooperative binding remain relevant to research with an
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appreciation that the specific states pertinent for allostery with cooperativity within the
symmetry and sequential models are likely to correspond to the favourable states in the
energy landscape.
1.1.4 Feedback Inhibition
The ensemble nature of proteins is also relevant for the explanation of feedback
inhibition, another type of allostery not necessarily involving cooperativity. Feedback
inhibition, or end-product inhibition, is the negative control of a molecule’s synthesis by
the last product in the pathway inhibiting the first committed step in the biosynthesis
(Figure 1.6) [5]. Feedback inhibition is a nearly instantaneous effect that is independent
of transcription, translation and signal transduction cascades, allowing it to be one of
the most efficient flux control mechanisms in biochemical pathways[58–60]. This makes
study of feedback inhibitors useful for advancement in allosteric small molecule design,
chemical and genetic tools, synthetic biology regulation and disease therapeutics[58].
Figure 1.6: Schematic representation of end-product inhibition in a three-step enzyme
pathway. Substrate 1 (orange triangle) binds to enzyme 1 to form intermediate substrate
1 (green square). Intermediate substrate 1 can bind to enzyme 2 to form intermediate
substrate 2 (purple shape). Intermediate substrate 2 can bind to enzyme 3 to form the
end product (blue circle). The end product is capable of inhibiting enzyme 1.
Feedback inhibition allows the pathway to regulate and control the synthesis of product
formation, so overproduction does not occur. When product is present in the cell (and
therefore not being used up immediately) feedback inhibition signals a cessation or
reduction of the molecule’s production by binding to the initial enzyme in the pathway
and inhibiting or slowing down further synthesis [5]. Reversible binding allows the
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production to begin again at a time when the levels of the end-product decrease. This
saves valuable cell resources such as carbon, nitrogen, and energy from unnecessary
assembly of products not immediately required [60]. Since feedback inhibition directly
utilises product to affect the starter enzyme it may be supposed that orthosteric
inhibition would be the simplest way for product binding, with substrate and product
vying for the same binding site. However, with pathways many steps long, the product
is often very chemically distinct from its initial substrate [60]. This poses a challenge
for orthosteric inhibition since accommodating both substrate and product in high
affinity, across the diverse array of flux-controlling enzymes, is not trivial. Allostery
is an effective tool to overcome this. Interestingly, feedback inhibition was discovered
before the concept of allostery was formulated and before the focus of its explanation by
cooperativity made the forefront of the field. The first instance of feedback inhibition
was reported in 1954 by Brooke, Ushiba and Magasanik regarding feedback inhibition
in bacterial pyrimidine biosynthesis [61] with supporting evidence following closely
in the year after. For example, Novick and Szilard showed that the first enzyme in the
system was responsible for this control [62]. Similarly, Roberts et al. conducted a study
using E. coli with all carbon compounds in the cell 14C-labelled [63]. Upon addition
of unlabelled end-product, endogenous biosynthesis was down-regulated with the cell
exclusively favouring use of the exogenous end-product source. Following these key
observations, many systems were interrogated and found to have feedback inhibition.
The most studied of these, aspartate carbamoyltransferase (ATCase), was demonstrated
to control pyrimidine biosynthesis by measuring activity under exogenously controlled
end-product supply [64]. Feedback inhibition is a quick and simple way to control
metabolism and has since been found to be widespread. Feedback inhibition is abundant
in bacterial biosynthetic pathways for products such as amino acids, nucleotides and
even isoprenoids [65]. Almost all bacterial amino acid biosynthesis utilises feedback
inhibition. For example, tryptophan biosynthesis [66], valine biosynthesis [67] and
histidine biosynthesis [68].
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1.2 Histidine Biosynthesis and the Role of ATP
Phosphoribosyltransferase
1.2.1 Histidine Biosynthesis Pathway
The histidine pathway is a nine-step biosynthesis (Figure 1.7) beginning with the Mg2+-
dependent nucleophilic attack of adenosine 5’-triphosphate (ATP) N1 on 5-phospho-
α-D-phosphoribosyl-1-pyrophosphate (PRPP) C1 catalysed by the flux-controlling
enzyme ATP phosphoribosyltransferase (ATPPRT) (EC: 2.4.2.17) (Figure 1.8). This
reversible reaction producing N1- (5-phospho-β-D-ribosyl)-ATP (PRATP) and inorganic
pyrophosphate (PPi) strongly favours reactants but is followed by eight further steps
to synthesise L-histidine. Hydrolysis of the α – β phosphate linkage, then further
hydrolysis to open the six membered ring to give phosphoribosyl-AMP, is carried out
by the bifunctional phosphoribosyl-ATP pyrophosphohydrolase/phosphoribosyl-AMP
cyclohydrolase (EC: 3.6.1.31/EC: 3.5.4.19) in some organisms (e. g. Psychrobacter
arcticus and Staphylococcus aureus), while in others (e. g. Mycobaterium tuberculosis
and Escherichia coli) each activity is present in a unique polypeptide. The
subsequent steps are carried out by phosphoribosylformimino-5-aminoimidazole
carboxamide ribotide isomerase [EC: 5.3.1.16], imidazole glycerol-phosphate synthase
[EC:4.3.2.10], imidazoleglycerol-phosphate dehydratase [EC: 4.2.1.19], histidinol-
phosphate aminotransferase [EC: 2.6.1.9], histidinol-phosphate phosphatase [EC:
3.1.3.15] and histidinol dehydrogenase [EC: 1.1.1.23] [6, 69].
The histidine pathway forms an essential connection between amino acid, purine, and
thiamine biosynthesis [71]. It is one of the most highly regulated amino acid biosynthesis
systems due to also being one of the most energetically consuming anabolic pathways
[72]. The cost of synthesising one molecule of histidine (when histidine is not present
in the growth media) was determined to be around 41 molecules of ATP in Salmonella
typhimurium [73] and therefore stringent regulation of the pathway is essential to
conserve cell resources. The initial step in the pathway (coded for by the hisG gene)
is highly regulated by allosteric feedback inhibition by histidine. Some organisms
also have initial step competitive orthosteric inhibition by substrate analogues such
as AMP and ADP [74], product inhibition from PRATP [75] and positive cooperative
inhibition by guanosine tetraphosphate (ppGpp) when also in the presence of histidine
[76]. Interestingly, guanosine tetraphosphate accumulates when bacteria are starved for
amino acids and is a positive effector of his operon transcription [71]. Therefore, ppGpp
is an inhibitor of ATPPRT (the first committed step of the pathway) in the presence of
histidine, but a transcriptional effector in the absence of histidine.
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Figure 1.7: Histidine Biosynthetic pathway [6]. Enzymes: ATP
phosphoribosyltransferase (E1), phosphoribosyl ATP pyrophosphohydrolase (E2)
phosphoribosyl AMP cyclohydrolase (E3) phosphoribosylformimino-5-aminoimidazole
carboxamide ribotide isomerase (E4), imidazole glycerol-phosphate synthase (E5),
imidazoleglycerol-phosphate dehydratase (E6), histidinol-phosphate aminotransferase
(E7), histidinol-phosphatase (E8) and histidinol dehydrogenase (E9). Compounds: PRPP
(1), ATP (2), PRATP (3), phosphoribosyl-AMP (4), phosphoribosyl-formimino-AICAR-
phosphate (5), phosphoribulosyl-formimino-AICAR-phosphate (6), 5-aminoimidazole-4-
carboxamide ribonucleotide (AICAR) (7), imidazole-glycerol-phosphate (8), imidazole-
acetol-phosphate (9), L-histidinol-phosphate (10), L-histidinol (11), L-histidine (12).
In general, bacteria grown in minimal-glucose medium has four-fold greater his operon
expression than bacteria grown in rich medium and thus the growth rate of the cell
is related to the metabolic regulation of the cell in response to the overall amino-acid
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Figure 1.8: ATPPRT-catalysed reaction is inhibited by the product of the pathway,
histidine [70].
supply in the cell [77]. In minimal medium conditions, the rate of histidine biosynthesis
is chiefly controlled by regulation of HisG enzymatic activity [71]. Since histidine
biosynthesis is regulated mainly by modulating the flow of intermediates through the
pathway [71], this array of inhibiting molecules of the initial step allows delicate control
of the rate of histidine biosynthesis across a variety of cellular metabolic states. However,
histidine biosynthesis is also regulated through his operon expression. The his operon
is comprised of a cluster of structural genes required for histidine biosynthesis (Figure
1.9[78]) and its expression is upregulated when the bacteria is starved of histidine [79].
It is generally accepted that two mechanisms at the transcription level are responsible
for the regulation of the his operon [71]. The first regards transcription ignition by the
textithis operon primary promoter (hisp1) through concentration change of ppGpp. The
second regards transcription of the his structural genes by an attenuation mechanism
vigilant of intracellular concentrations of His-tRNAHis. His-tRNAHis concentrations
fluctuate in response to cellular histidine concentration, histidyl-tRNA synthetase and
chromosomal DNA supercoiling levels in response to anaerobiosis and osmolarity [71].
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Histidine insensitive mutants of HisGL have previously been prepared to
increase histidine production for industrial and biochemical uses in strains such as
Corynebacterium glutamicum, Brevibacterium flavum, Serratia marcescens and Escherichia
coli[80]. Initially, basic cloning techniques to isolate mutants with histidine insensitivity
were utilised for industrial strain preparation, for example A PRT deficient mutant of
C. glutamicum was shown to produce twice as much histidine by batch fermentation
as the wild type[81]. More recently, specific residue mutations (N215K/L231F/T235A)
designed to disrupt histidine binding to ATPPRT in C. glutamicum resulted in 37-fold less
histidine sensitivity than the wild type with no appreciable change to enzyme activity
[82]. These or similar strains are still in use [83] but histidine sensitivity is not the only
modification available to improve histidine production in bacterial strains. An example
of an alternative approach to improved histidine yield utilised HisE271K , an E.coli strain
insensitive to histidine but susceptible to inhibition by AMP, ADP and AICAR. By
purH and purA gene overexpression and a modified PitA-dependent phosphate/metal
transport system (via a pitA gene deletion), a new E. coli strain capable of increased
histidine accumulation was developed[80].
Figure 1.9: Schematic representation of the organisation of the histidine biosynthetic
genes in E. coli and Salmonella typhimurium bacteria. The schematic is labelled as follows.
Black box depicts leader sequence and white boxes depict the structural gene. Lines
between genes indicate intergenic regions [78].
1.2.2 ATP phosphoribosyltransferases
ATPPRT is part of the phosphoribosyltransferase (PRT) superfamily which mediate
reactions involving the transfer of phosphoribosyl groups to nitrogen moieties[72].
ATPPRT specifically transfers the phosphoribosyl moiety of PRPP to ATP to produce
PRATP [70].
Long- and Short-Form ATPPRTs
ATPPRTs appear in one of two genetically distinct forms. HisGL is termed the ‘long form’,
is homo-hexameric and around 300 amino acids in length whereas HisGS is shorter at
around 200 amino acids [84] and is a homodimer with each subunit comprising of a C-
terminus regulatory domain and a catalytic domain. The discrepancy in chain length is
around 100 residues found at the C terminus in the long form but not in the short form
[85], which is responsible for allosteric inhibition of HisGL [86]. HisGS and HisGL share
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∼25% sequence identity [70] and these regions of similarity are found in the homologous
catalytic domains [87].
The long-form is a fully catalytically active enzyme [69] encoded by the hisG gene and
is the most studied form of the enzyme [86]. The ‘short-form’is also encoded by the
hisG gene but a different variant to HisGL, one which lacks the C-terminal domain.
HisGS is catalytically active but insensitive to histidine [88, 89] and requires allosteric
activation by its regulatory protein, HisZ (encoded by the hisZ gene) to reach maximum
catalytic activity and regulate histidine feedback inhibition [85]. The short form ATPPRT
holoenzyme exists as a hetero-octameric protein comprising of two HisGS dimers and a
HisZ tetramer [20, 84, 90]. The four HisZ subunits sit as a cross-shaped tetramer in the
middle of the structure with two HisGS dimers flanking top and bottom (Figure 1.10).
HisZ is solely a regulatory protein. It does not contain a catalytic domain (so is inactive on
its own), is not found in species containing HisGL or in species which cannot synthesise
histidine [84].
Until recently it was thought that HisGS was only able to catalyse the ATPPRT reaction
after forming the non-covalent octameric complex with regulatory protein HisZ [87].
However, at least in the cases of Psychrobacter arcticus [20] and Lactococcus lactis (L.lactis)
[91], HisGS can catalyse the reaction alone but at considerably lower rates than in
conjunction with HisZ. Alone, HisGS forms homodimers that are insensitive to histidine
but when in complex with HisZ, the ATPPRT is histidine sensitive [20, 91]. HisZ is
responsible for the histidine feedback inhibition and is therefore responsible for both
activation and inhibition of short-form ATPPRTs.
Figure 1.10: Schematic representation of short form ATPPRT structure formation from
two HisZ dimers and two HisGS dimers.
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Evolution of ATPPRT
Whether an organism has a short or long form of HisG is based on the organism’s
evolution. The short form is most commonly found in archaea but also in some bacteria
(including S. aureus and P. arcticus) and the long form is most commonly found in
bacteria (such as E. coli) and histidine-producing eukaryotes [58, 68, 86, 92–94]. Both
HisGL and HisGS/HisZ (the ATPPRT apoenzyme) have greatly reduced activity in the
presence of histidine due to feedback inhibition [69].
HisGS evolved separately [84] from HisZ, but also separately from other classes of
PRT. The only protein with clear evidence of a shared ancestor to HisGS is HisGL [84].
They are both likely to have descended from a common ancestor with the periplasmic
binding protein (PBP II) family which includes phosphate and sulphate binding proteins
(although none of the PBP IIs show PRT function) [95].
HisZ and histidyl-tRNA synthetase (HisRS) are paralogs [70, 85] and so are encoded by
genes that are derived from the same ancestral gene. HisZ does not have aminoacylation
activity (or any other catalytic activity) but like HisRS, it contains the similar histidine-
binding motifs characteristic of tRNA synthetases [87]. It is most likely that ATP and
tRNA binding were removed during the evolutionary path. Some HisZs have greater
similarity to HisRS than others, for example, there are a subset of short form ATPPRTs
whose HisZ subunits lack a C-terminal domain found in many other HisZs and HisRS.
HisZs with this C-terminal domain have similar regulatory properties to those without
and are still histidine sensitive [86] so it is unclear what specialised function, if any, these
extra residues are responsible for.
Allostery of ATPPRTs
Previous allosteric study of ATPPRTs has focused on the long form of the enzyme. There
is currently no clear consensus on the exact mechanism of allostery in ATPPRT. There
are two proposed mechanisms, one where ligand binding causes a large conformational
change stabilizing one oligomeric state and another suggesting no change in oligomeric
order but local conformational changes capable of tightening the overall structure. In
the case of Mycobacterium tuberculosis, interconversion of dimer-hexamer states does not
account for the allosteric inhibition seen in the presence of histidine [69] and is more
likely a shift between two hexametric states varying by a domain III shift, an overall
tightening and subtle conformational changes upon binding of histidine[94]. Allosteric
histidine binding is thought to trap the enzyme in a form that is inactive but still
capable of catalysis, since upon increasing concentrations of histidine, a decrease in the
amplitude of the burst phase in pre-steady state kinetics is observed [58]. The presence
of a burst phase indicates that product release is rate limiting for M. tuberculosis HisGL.
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In the case of C. jejuni however, there is evidence from computational and mutagenesis
approaches to suggest that a hinge twist within the flexible catalytic domain creates
distinct conformational ensembles. These population shifts have varying dynamic
properties and are capable of facilitating the allosteric response[96]. On the basis of these
two key studies, there is suggestion that the latter proposed mechanism of small localised
changes is more likely to be the underlying allostery mechanism in ATPPRTs than a large
conformation change to stabilise one oligomeric state over another. Further analysis of
ATPPRTs from a wider array of organisms is required to determine the validity of this
statement.
1.2.3 Psychrobacter arcticus
P. arcticus, a gram-negative, rod-shaped, heterotrophic, psychrophilic bacterium from
the Siberian permafrost [97] which grows between at -10 and 28°C. P. arcticus was the
first cold-adapted bacterium to have its genome sequenced and has been used as a cold-
adapted model [97–99] due to its abundance in permafrost and to its growth condition
in the wild being always under sub-zero temperatures. Compared to mesophilic
bacteria, psychrophiles can have differences in membrane composition, contain cold
shock proteins[97], better utilise acetate as a carbon source[99], have a lower frequency
of amino acids such as proline and arginine in their proteins [100] and have increased
protein flexibility at low temperature, at least in the outer shells of the protein. P.
arcticus contains a short-form ATPPRT, as does Staphylococcus aureus and Acinetobacter
baumannii, both of which urgently require new antibiotics. Study of P. arcticus ATPPRT
(which is regulated by both allosteric inhibition and activation) is therefore useful as a
model to provide insight into a valuable drug target but also allosteric intricacies. P.
arcticus has been studied extensively in the da Silva lab [20, 101, 102] to shed light on
short-form ATPPRT kinetics, structure, mechanism and allostery with a view to improve
histidine biosynthesis industrially. All purification protocols are already established and
so in the interest of time and resources, PaATPPRT was used for the present study.
1.2.4 Structure of Psychrobacter arcticus ATPPRT
Similarly to Thermotoga maritima ATPPRT [84] and Lactococcus lactis ATPPRT [103], the
PaATPPRT apoenzyme is a hetero-octamer comprising of two HisGS dimers flanking top
and bottom of a HisZ tetramer which sits crossed, in a head-to-tail arrangement, at the
centre (Figure 1.11) [20]. The HisGS subunits have two domains [20] which is in line with
Thermotoga maritima ATPPRT [84] and Lactococcus lactis ATPPRT [70] but also HisGL
catalytic domains [104, 105]. The HisZ subunits contain a large N-terminal domain and
smaller C-terminal domain [20]. This is the same as HisRS but not Thermotoga maritima
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Figure 1.11: PaATPPRT quaternary structure. Four HisZ subunits (yellow, blue, cyan and
green) sit crossed in the centre of the hetero-octamer with two pairs of HisGS subunits
(red and orange) flanking top and bottom.
ATPPRT [84] or Lactococcus lactis ATPPRT [70]. The latter two have not retained the
C-terminal domain during evolution.
Structure of Psychrobacter arcticus ATPPRT:PRPP
The active site of PaATPPRT is very similar to that of PaHisGS alone and the other
characterised ATPPRTs [72, 86, 106–108]. The structures of both PaHisGS and
PaATPPRT bound to PRPP, PRPP:ATP, and PRATP have been published [101]. No
PaATPPRT structure with ATP (or its alternative substrate ADP) bound in the active site
could be obtained which suggests PRPP may be required to bind first.
When PRPP is bound to PaATPPRT the substrate is secured to the active site via main and
side chain interactions between the PRPP binding loop and the phosphate tail of PRPP.
There is also a hydrogen bond (H-bond) that stops PRPP from blocking the ATP binding
site between the substrate 2-OH group and side chain residue Asp176. This is similar to
the PRPP bound structure of L. lactis [107] and PaHisGS alone, but not C. jejuni [86].
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Structure of Psychrobacter arcticus ATPPRT:PRPP:ATP
The PaATPPRT:PRPP:ATP bound structure is similar to PaATPPRT:PRPP but the Asp32-
Asp176 H-bond has been broken by the Arg 32 side chain rotating 180° around it’s
cγ-cδ axis with its guanidinium group now sitting parallel to the adenine ring. An
Arg132-Arg179 salt bridge keeps the ATP site clear (Figure 1.12, B). This is found in
the CjATPPRT :ATP bound structure[106] and is a conserved residue across ATPPRTs.
Asp94 H-bonds to the 2’OH and 3’OH of ATP (also true of C. jejuni and Mycobacterium
tuberculosis (M. tuberculosis) [86, 106] and a Lys137 salt bridge with beta-PO4.
Figure 1.12: Enlarged view of the active-site of PaATPPRT bound to (A) PRPP, (B)
PRPP:ATP, (C) PRATP and of PaHisGS bound to (D) PRPP, (E) PRPP:ATP and (F) PRATP.
The figure shows polar interactions (grey dashed lines), magnesium ions (green spheres),
nitrogen atoms (blue), oxygen atoms (red), phosphorus (orange), ligands (stick models
carbon atoms are cyan), protein backbone (grey ribbon diagram with selected residues
from main and side chains shown as stick models, carbon atoms are grey), side chains of
two Arg residues contributed by the adjacent subunit (stick models with carbon atoms in
magenta). Residues whose interactions with ligands are absent in the PaHisGS structures
are labelled in the PaATPPRT structures and vice versa [101].
There is further stabilisation from a salt bridge between the γ-PO4 and Arg73
on an adjacent PaHisGS subunit, but this may not be significant as a comparable L.
lactis mutant, lacking the capability to form the salt bridge, had no significant binding
differences. ATP and PRPP are brought into proximity for reaction by a salt bridge
between Arg32 and α-PO4 groups of both substrates. Additionally, the electrostatic
repulsion from the negatively charged phosphate groups is reduced by a Mg2+ ion
coordinated between the α and β-PO4 of both substrates. Arg32 is the only residue to
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interact with the PPi moiety – it is likely that another Mg2+ ion is required to stabilize
the PPi leaving group but this was not observed in the crystal structure. This ternary
complex structure has not converted to product because the adenine ring is bound
with the N1 ATP facing away from the PRPP C1 (the site of nucleophilic attack). This
anticatalytic rotamer could be reason this structure was trapped with both products in
the active site but it could also be because the reaction favours the reactants. In solution
the necessary orientation for catalysis would be able to be sampled but the crystal form
probably lacks the flexibility. This is not unique to PaATPPRT however, C. jejuni also
showed electron density for both substrates in the active site [86].
In a ternary complex with its alternative substrate ADP, ADP mimics the orientation
of ATP in the binding site. Almost all interactions except the Arg73 salt bridge are
preserved, including coordination to Mg2+. The Arg73 on the neighbouring subunit
is in the same position but is too far away to reach beta-PO4 of ADP. Considering
PRPP:ADP:PaHisGS and PRPP:ADP:PaATPPRT (Figure 1.13) structures were obtained
where the ADP binds in a similar mode as ATP does. This suggests that ADP may be a
substrate replacing ATP, and not an inhibitor as is the case with HisGL-based ATPPRTs
[109] since it can bind in the same active site with similar contacts.
Figure 1.13: Enlarged view of active-site of PaATPPRT bound to PRPP:ADP. The figure
also shows magnesium (green spheres) nitrogen atoms (blue), oxygen atoms (red),
phosphorus atoms (orange), ligands (stick models, carbon in cyan), protein backbone
(ribbon diagram with selected main and side chain residues as stick models, carbon in
grey) [101].
In the PaATPPRT :PRPP bound structure and the PaATPPRT :PRPP:ATP bound there is
an additional H-bond between Glu163 and the 3-OH group (which likely helps position
the substrate for catalysis) that is not seen in the solitary PaHisGS :PRPP bound structure.
The PPi moiety of the PRPP is very flexible and has no observed specific interaction
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with the protein, only one interaction overall – with a water molecule that also interacts
with the less flexible 5-phosphoribosyl moiety [101]. Structure of Psychrobacter arcticus
ATPPRT:PRATP
In the PaATPPRT :PRATP bound structure, density for the entire product was observed
(there is a similar structure for C. jejuni which also shows product electron density[86]).
However, the Mg2+ ion density could not be definitively assigned but it is thought to
be similarly to PaHisGS alone whereas in the PRATP bound structure the Mg2+ ion is
coordinated to the α- β- and γ-PO4 of PRATP. Overlay showed good overlap between
the Mg2+, phosphoribosyl and triphosphoribosyl moiety position in all structures. There
is however a 1.6 A shift of the η-NH group of Arg32 towards the PRPP binding site.
There is still a parallel relationship between the adenine ring and the guanidinium, but
a H-bond is now donated to O4” of PRATP.
1.2.5 Activation and Mechanism of PaATPPRT
Figure 1.14: Overlay of PaHisGS dimers from PaATPPRT and PaHisGS alone bound to
PRPP, ATP and Mg2+. (A) Overlay of PaHisGS dimers of non-activated PaHisGS (grey)
and activated PaATPPRT (magenta). (B) Enlarged view of overlay comparison of non-
activated and activated PaATPPRT active sites showing position change of Arg56 and
Arg73 residues in PRPP:ATP bound structures. Polar interactions are shown by dashed
lines, magnesium ions (green spheres), non-activated PaHisGS (grey) and activated
PaATPPRT (magenta), Arg56 and Arg73 side chains (stick models with nitrogen in blue,
oxygen in red, phosphorus in orange, and carbon in magenta (PaATPPRT) and grey
(PaHisGS ).
There is little variation in structure between PaHisGS non-activated) and PaATPPRT
(activated) despite the presence of HisZ leading to a large activation of PaHisGS [101]
(Figure 1.14, A). There is an observed tightening of the overall PaHisGS dimer upon HisZ
binding which increases the cross-dimer contacts of some side chains (Figure 1.14,B). The
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structures of both PaHisGS (non-activated) and PaATPPRT (activated) bound to PRPP,
PRPP:ATP, and PRATP are similar, with substantial differences only manifested in the
PRPP:ATP bound structures (Figure 1.12).
Based on these structures [101] it is proposed that PRPP binds to the enzyme first before
ATP binding can occur. This is incongruent with published long form ATPPRT HisGL
structures C. jejuni and M. tuberculosis [86, 106] (which shows ATP binding first in
an ordered Bi-Bi kinetic mechanism[110] but supported by the only other short form
ATPPRT:PRPP complex published: Ł.lactis[91]. Product release, however, follows the
same pattern as both long and short form ATPPRTs previously published [86, 91, 107]
with PPi leaving first, followed by PRATP. This hypothesis has been corroborated by
kinetic interrogation [102] Kinetic analysis by initial velocity studies with both substrates
determined PaHisGS alone forms a ternary complex with both substrates in the active site
congruently and that binding is sequential. Binding of PRPP to PaHisGS was detected
by isothermal calorimetry (ITC) whereas binding of ATP to PaATPPRT could be not be
established. Similarly, differential scanning fluorometry (DSF) detected stabilisation of
Tm upon PRPP binding but not ATP. Given the extensive similarity between PaHisG
crystal structures and PaATPPRT, the mechanism is assumed to be the same for both.
The kinetic mechanism of PaHisGS and PaATPPRT is summarised in Figure 1.15.
Figure 1.15: Proposed reaction scheme of PaATPPRT.
Replacing Mg2+ in the buffer with Mg2+ does not affect the rate of PaATPPRT reaction
therefore the rate limiting step is unlikely to be the stabilisation of phosphate groups.
This is the case however for PaHisGS , which showed an increase in rate when Mn2+ was
used. A stronger Lewis acid stabilises charges more efficiently, leading to a faster rate of
PRATP production. The rate limiting step for PaHisGS is therefore the interconversion
between the PaHisGS :PRPP:ATP and PaHisGS :PRATP:PPi ternary complexes. The




The current work investigates the mechanism of histidine inhibition in PaATPPRT
through steady-state and pre-steady-state kinetics, thermal-shift assays, and X-ray
crystallography. Inhibition by AMP and activity with ADP are also characterised. These
findings provide the best characterisation of inhibition in a HisGS-based ATPPRT, and
may be useful as a model to understand disease-relevant ATPPRTs. For example,
Acinetobacter baumannii, which belongs to the same bacterial family as P. acticus
(Moraxellaceae), is at the top of the World Health Organisation (WHO) list of the “dirty
dozen”, a list of 12 bacterial species against which novel antimicrobials are desperately
needed [111]. A. baumannii has a short-form ATPPRT of which HisGS and HisZ share
70% and 43% sequence identity with their P. arcticus counterparts, respectively. Recently,
HisZ has been shown to be essential for A. baumanii survival, and HisGS essential
for A. baumannii persistence in the lung, which is a requirement for virulence in this
species[111]. Therefore, targeting ATPPRT could be a strategy to thwart A. baumanii
infection, and given the high similarity between A. baumanii and P. arcticus ATPPRTs,
the mechanistic inferences from this work could aid drug design. Furthermore, in vivo
histidine production without feedback inhibition would be a lucrative avenue for amino
acid production. Therefore, the current work not only delivers insight into inhibition of
short-form ATPPRTs but provides relevant information for biotechnology approaches to






ATP, PRPP, adenosine 5’-triphosphate (ADP), L-histidine, 3-(2-thienyl)-L-alanine (TIH),
MgCl2, dithiothreitol (DTT), and tricine were purchased from Sigma-Aldrich. HEPES
and NaCl were sourced from Formedium. EDTA-free Cφmplete Protease Inhibitor
Cocktail was purchased from Roche and Bug Buster, from Merck. A Gibson Assembly
kit was purchased from New England Biolabs. All primers were from IDT and all
commercially available enzymes were from Thermo Fisher Scientific or New England
Biolabs. Mycobacterium tuberculosis inorganic pyrophosphatase (MtPPase) was purified
in-house as previously published [20]. Unless otherwise stated, all other reagents were
purchased from readily available commercial sources and all were used without further
purification. Expression vectors and g-block DNA were ordered from DNA 2.0.
2.1.2 Materials and Equipment
Ultrafiltration membranes were manufactured by Millipore and dialysis cassettes were
Slide-A-LyserTM purchased from Thermo Fisher Scientific. Centrifugal filter units were
manufactured by Amicon. The high-pressure cell disruptor used for cell lysis was
produced by Constant Systems. All protein purifications were carried out using an
AKTA Start FPLC system and all nickel columns were purchased from GE Lifesciences.
Kinetic experiments were carried out on either a UV-2600 spectrophotometer outfitted
with a CPS unit for temperature control (Shimadzu) or an SX-20 stopped-flow
spectrophotometer fitted with a 5 µL mixing cell (0.5-cm path length and 0.9-ms
dead-time) by Applied Photophysics. Unless otherwise stated, all other materials were
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purchased from readily available commercial suppliers.
2.1.3 Services
All mass spectrometry analysis was carried out by the BSRC Mass Spectrometry Facility
at the University of St Andrews. All DNA sequencing was undertaken by Eurofins
Genomics using their Mix2Seq kit.
2.1.4 Plasmid, Protein and Primer Sequences
Plasmid Sequences
Expression vectors pJexpress414 and pJexpress411 containing the DNA sequences
encoding for SaHisZ and SaHisGS , respectively, with an N terminus 6-histidine tag
(6xHis-tag) and tobacco etch virus protease (TEVP) cleavage site were ordered from
DNA 2.0 with codon-optimisation for expression in Escherichia coli.
Expression vectors pJexpress414 and pJexpress431 containing the DNA sequences
encoding for PaHisZ and PaHisGS , respectively, with an N terminus 6-histidine tag
(6xHis-tag) and TEVP cleavage site were ordered from DNA 2.0 with codon-optimisation
for expression in E. coli.
Primer Sequences
SaHisGS MBP Primer 1 Reverse
5′- TCG TAT TAA TTT CGC GGA AGG -3′
SaHisGS MBP Primer 2 Forward




5′-CAT TTA AAG GCC AGC CTA GCA-3′
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Mass and extinction coefficients at 280 nm (ε280) expressed proteins were calculated by
the software ProtParam. The 6xHis tagged proteins were cleaved by TEV protease using
the recognition sequence ENLYFQ\G, where \ denotes the cleavage site. The sequences
presented below also contain a \ to denote the TEV Protease cleavage site.
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2.2 General Purification and Plasmid Engineering Methods
2.2.1 Starter Culture
LB medium (5–10 mL) containing either Ampicillin (100 µg/mL) or Kanamycin (50
µg/mL) was inoculated with a colony grown in LB agar, also containing Ampicillin (100
µg/mL) or Kanamycin (50 µg/mL), or from a glycerol stock (made up of 500 µL of a
previous starter culture and 500 µL of 50% (v/v) glycerol solution and stored at −80 ◦C)
and incubated in a shaker for 16 hours at 37 ◦C. The antibiotics used with each plasmid
are shown in Table 2.1.
Table 2.1: Corresponding antibiotic for expression plasmids and strains
Plasmid/Strain Antibiotic Conc. (mg/mL)
pJexpress411 plasmid Kanamycin 50
pJexpress414 plasmid Ampicillin 100
pJexpress431 plasmid Kanamycin 50
Origami 2 cells Tetracycline 12.5
2.2.2 Culture Growth
LB medium (either 50 mL for expression test or 1 L for protein purification) containing
antibiotic at the same concentration as starter culture was inoculated with starter culture
(1–5 mL) and incubated in a shaker at 37 ◦C until the optical density at 600 nm (OD600)
of the culture reached 0.4–0.6 for expression at 37 ◦C, or OD 0.6–0.8 for expression at
15–20 ◦C. Cultures were equilibrated to the desired expression induction temperature,
if other than 37 ◦C, prior to addition of 0.11 mM isopropyl β-D-1-thiogalactopyranoside
(IPTG) and incubated in a shaker for 16 hours at the induction temperature. Cells were
harvested by centrifugation (6800 g, 15 min), the supernatant was discarded, and pellets
stored at −20 ◦C.
2.2.3 Expression Tests
One aliquot (1 mL) per culture was removed just before induction, centrifuged (∼16,000
g, 1 min), supernatant discarded and pellet stored at −20 ◦C (control sample). This
procedure was also carried out with post-induction culture (expression sample).
Cell pellets were resuspended in 100 µL of lysis buffer (Section 2.3), agitated gently for
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20 min, centrifuged (16,000 g, 30 min) and the supernatant collected. The resulting
cell pellets were resuspended either in 50 µL (control sample) or 100 µL (expression
sample) of 10 mM Tris HCl pH 7.5. Samples were analysed by SDS-PAGE (either with
the Invitrogen NuPage system or the Bio-Rad Criterion system).
2.2.4 Buffers for Protein Purification
Buffer A1: 50 mM HEPES, 500 mM NaCl, 10 mM Imidazole, pH 8.
Buffer A2: 20 mM HEPES, 150 mM NaCl, pH 8.
Buffer B: 50 mM HEPES, 500 mM NaCl, 500 mM Imidazole, pH 8.
Dialysis Buffer 1: 20 mM HEPES, 150 mM NaCl, 2 mM DTT, 10 % Glycerol (v/v), pH 7.5.
Dialysis Buffer 2: 20 mM HEPES, 150 mM NaCl, 10 % Glycerol (v/v), pH 8.0.
2.2.5 Protein Purification of 6xHis-tagged Proteins
All procedures were carried out at 4 ◦C. The protein of interest was purified from the
cell pellet by thawing on ice and resuspending in Buffer A (20 mL per cell pellet from
1 L of culture) containing EDTA-free protease inhibitor cocktail (Cφmplete, half tablet).
Lysozyme (0.2 mg/mL) and DNase I (0.05 mg/mL) were added to the suspension and
stirred for 30 min. The cells were disrupted by passage through a high-pressure cell
disruptor (emulsifier) before centrifugation (48000 g, 30 min). The supernatant was
collected, filtered in a 0.45 µm membrane and an aliquot (10 µL) stored (4 ◦C) as a pre-
column sample. The sample was loaded onto a HisTrap FF 5 mL column, washed with
10 CV of Buffer A and eluted with a gradient of 20 CV of Buffer B (0–60%).
2.2.6 Protein Purification with TEVP 6xHis-tag Cleavage
Protein purifications incorporating TEVP cleavage of 6xHis-tagged proteins were
initially purified as in Section 2.2.5. Fractions containing the desired protein were
pooled and concentrated using a 10000 or 30000 molecular weight cut-off (MWCO)
ultrafiltration membrane. The sample was dialysed overnight in 10000 or 30000 MWCO
dialysis cassettes, or dialysis tubing, against 2 × 2 L of Dialysis Buffer 1. TEVP from
in-house purification [20] was added slowly over multiple days to a final ratio of ∼10:1
tagged protein to TEVP. The cleavage was dialyzed against fresh 2 L of Dialysis Buffer 1
before every TEVP addition. After cleavage the protein was dialysed into 2 × 2 L of Buffer
A then centrifuged (48,000g, 30 min), filtered through 0.45 µm membrane and loaded
onto a HisTrap FF 20 mL column (GE) pre-equilibrated with Buffer A. The flow through
was collected and analysed by SDS−PAGE. Fractions containing the desired protein were
pooled and concentrated using a 10000 or 30000 MWCO ultrafiltration membrane before
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being dialyzed 3 × against 2 L of 20 mM HEPES (pH 8.0). The protein was aliquoted and
stored at 80 ◦C.
2.2.7 Agarose Gel Electrophoresis Procedure
For agarose gel electrophoresis, 1% agarose gel (m/v) was prepared using TBE (Tris-
borate-EDTA) buffer containing 0.06% Peqgreen stain (v/v). Gels were run at 80 V for 1
hour and visualised under UV light.
2.3 Expression and Purification Trials
2.3.1 SaHisZ Expression Test Growth Condition Trials
The expression test conditions outlined in Table 2.2 were tried for the SaHisZ.
Table 2.2: SaHisZ Expression Test Growth Conditions
E. coli Strain Plasmid Media Temp. (◦C) [IPTG]
(mM)
Lysis Buffer
BL21(DE3) SaHisZ-pJexpress414 LB 37 1 Bug Buster
BL21(DE3) SaHisZ-pJexpress414 LB 16 0.5 Bug Buster
SaHisZ Purification Trial
SaHisZ was purified using the general purification method for a 6xHis-tagged protein
requiring cleavage by TEVP (Section 2.2.6) with the following changes. After the first
nickel column and ultrafiltration step the protein solution was centrifuged (48,000 g,
30 min) before dialysis (in dialysis tubing) into Dialysis Buffer 1 and addition of TEVP
(7.6 mg). After two days cleaving with TEVP the protein solution was dialysed into
Dialysis Buffer 2 for 2 hours then centrifuged (48,000 g, 30 min). Soluble and insoluble
fractions were analysed by SDS-PAGE then cleavage by additional TEVP (3.8 mg). The
purification was continued with the soluble fraction dialysed into 2 L Buffer A2. A
further aliquot of TEVP (1.9 mg) was added and left to dialyse in fresh Buffer A2 for 2
days. The solution was filtered and run on a nickel column and analysed by SDS-PAGE.
All fractions containing SaHisZ were pooled and re-run on a third nickel column as in
Section 2.2.6. Finally, the protein solution was loaded onto a HiPrep 26/60 Sephacryl
S300 HR gel filtration column with 20 mM HEPES (pH 7.5) and analysed by SDS-PAGE.
Fractions containing SaHisZ were dialysed and stored as in Section 2.2.6. Bands from
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the final SDS-PAGE were excised and sent for protein identification and intact mass
determination and by mass spectrometry and protein identification by gel band digestion
with trypsin, electrospray ionisation mass spectrometry (ESI-MS) and a Mascot search
with comparison to the NCBI database.
2.3.2 SaHisGS Expression Test Growth Condition Trials
The expression test conditions outlined in Table 2.3 were tried for the given protein.
All strains trialled contained a λDE3 lysogen carrying the gene for T7 RNA
polymerase under control of the lacUV5 promoter. C43(DE3) is a strain specifically
engineered for recombinant proteins which may be toxic to BL21(DE3) cells (widely
used T7 E. coli expression strain) [112]. Origami 2(DE3) cells is a cell line with
additional folding apparatus [113]. BL21Gold(DE3) cells are a superior strain of
BL21(DE3) with two proteases capable of degrading recombinant protein removed [114].
BL21GoldPlysS(DE3) is similar but has shown to be advantageous for leaky expression
of toxic proteins [114].
Auto-Induction Method of Protein Expression
Stock solutions of 20x NPS solution (0.5 M (NH4)2SO4, 1 M KH2PO4, 1 M Na2HPO4) and
50x 5052 solution (2.71 M glycerol, 139 mM glucose, 292 mM α-lactose) were prepared.
Overnight culture (2 ml) of SaHisG-pJ411 Bl21(DE3) was added to 400 ml Auto-
induction Media (1 mM MgSO4, 1 x 5052 solution, 1x NPS solution, 50 g/ml Kanamycin,
ZY media to 400 ml) and agitated at 250 rpm and 16 ◦C for 48 hours. An aliquot (1 ml)
was removed from each flask and processed with Bug Buster using the general expression
test procedure (Section 2.2.3). The remaining volume of culture was centrifuged (6800 g,
15 min), the supernatant discarded and the cell pellet resuspended in Buffer A (20 ml).
The samples were passed twice through an emulsifier, centrifuged (4800 g, 30 min) and
the supernatant decanted and stored. A small scraping of the cell pellet was resuspended
in Tris HCl (10 mM, pH 7.5, 200 ml) for SDS-PAGE. SDS-PAGE was performed for both
sets of lysis conditions. This was repeated for SaHisZ-pJ414 BL21(DE3).
2.3.3 SaHisGS-pJexpress411 Plasmid Engineering
The sequence encoding for Maltose-binding protein (MBP) was inserted into the
SaHisGS-pJexpress411 plasmid to aid solubility of SaHisGS .
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Table 2.3: Expression test growth conditions for SaHisGS using SaHisGS-pJexpress411
E.coli Strain Media Temp. (◦C) [IPTG] (mM) Lysis Buffer
BL21(DE3) LB 37 1 Bug Buster
BL21(DE3) LB 16 1 Bug Buster
BL21(DE3) Auto-ind. 16 Auto-ind. Bug Buster
BL21(DE3) Auto-ind. 16 Auto-ind. Emulsifier
BL21(DE3) LB 37 0.5 Bug Buster
BL21(DE3) LB 16 0.5 Bug Buster
BL21(DE3) LB 37 0.1 Bug Buster
BL21(DE3) LB 16 0.1 Bug Buster
C43 (DE3) LB 37 0.5 Bug Buster
C43 (DE3) LB 16 0.1 Bug Buster
C43 (DE3) LB 37 0.5 Bug Buster
C43 (DE3) LB 16 0.1 Bug Buster
Origami 2(DE3) LB 37 0.5 Bug Buster
Origami 2 (DE3) LB 16 0.1 Bug Buster
Origami 2 (DE3) LB 37 0.5 Bug Buster
Origami 2 (DE3) LB 16 0.1 Bug Buster
SoluBL21(DE3) LB 37 0.5 Bug Buster
SoluBL21(DE3) LB 16 0.5 Bug Buster
BL21Gold(DE3) LB 37 0.5 Bug Buster
BL21Gold(DE3) LB 37 0.1 Bug Buster
BL21Gold(DE3) LB 16 0.5 Bug Buster
BL21Gold(DE3) LB 16 0.1 Bug Buster
BL21Gold(DE3)pLysS LB 37 0.5 Bug Buster
BL21Gold(DE3)pLysS LB 16 0.5 Bug Buster
C43 (DE3) TB 37 0.5 Bug Buster
C43 (DE3) TB 16 0.5 Bug Buster
C43 (DE3) TPB 37 0.5 Bug Buster
C43 (DE3) TPB 16 0.5 Bug Buster
C43 (DE3) LB & Mg2+ 37 0.5 Bug Buster
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PCR to Linearize Parent Plasmid
The samples in Table 2.4 were prepared in written order from the following stock
solutions: dNTP’s (10 mM), Phusion HF Buffer (5x, Thermo Fisher Scientific), Primer 2
F (10 µM), Primer 1 R (10 µM), SaHisGS-pJexpress411 (20 ng/µL), Phusion polymerase
(2 U/µL). Polymerase chain reaction (PCR) experiments of the samples were carried
out using the thermocycler program detailed in Table 2.5. The samples were stored at
−20 ◦C overnight before agarose gel electrophoresis was carried out. A Gene Ruler 1 KB
DNA ladder was used to determine the size of resulting fragments.
Table 2.4: PCR to linearize SaHisGS-pJexpress411 sample composition. C1 was a control














Annealing Temp. (◦C) 52 53.2 55 52 53.2 55 55 55
Sterile Water (µL) 68 68 68 65 65 65 69 69
dNTP’s (µL) 2 2 2 2 2 2 2 2
Phusion HF Buffer (µL) 20 20 20 20 20 20 20 20
Primer 2F (Tm = 52.9 ◦C) (µL) 5 5 5 5 5 5 5 5
Primer 1R (Tm = 51.7 ◦C) (µL) 5 5 5 5 5 5 5 5
DMSO (µL) 0 0 0 3 3 3 0 0
SaHisGS-pJexpress411 (µL) 1 1 1 1 1 1 0 1
Phusion Polymerase (µL) 1 1 1 1 1 1 1 0
Table 2.5: PCR conditions for SaHisGS-pJexpress411 linearization
Step Temperature (◦C) Time (s) Number of Cycles
Initial Denaturation 98 30 1
Denaturation 98 10
Annealing (Table 2.4) 30 30
Extension 72 30
Final Extension 72 600 1
Hold 4 N/A N/A
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Gibson Assembly of Linear SaHisGS-pJexpress411 with MBP G-Block
PCR sample 6 (55 ◦C with DMSO, Section 2.3.3), was digested overnight with Tango
buffer (10.5 µL) and DpnI (5 µL) at 37 ◦C. Two samples were prepared for Gibson
Assembly as in Table 2.6.
Table 2.6: Gibson Assembly sample compositions
Component 5x 10x Control
Sterile Water (µL) 6 4 10
SaHisGS-MBP G Block (µL) 2 4 0
Linear SaHisGS-pJexpress411 (µL) 2 2 0
Gibson Master Mix (µL) 10 10 10
The solutions were incubated in a thermocycler at 50 ◦C for 1 hour. The solution was
mixed with NEB 5-α chemically competent cells (50 µL) on ice for 30 min then heat
shocked for 32 s at 42 ◦C. SOC medium (300 µL) was added and the culture incubated
at 37 ◦C for 1 hour. The solutions were plated on LB agar plates containing 50 mg/mL
Kanamycin and incubated at 37 ◦C overnight.
Each colony was labelled with a letter (A–Z and α) and grown in LB media containing 50
mg/mL Kanamycin (5 mL) at 37 ◦C overnight. To pellet the cells, 5 mL was centrifuged
at 16000 g for 1 min and the supernatant discarded.
Plasmid Purification of Gibson Assembly DNA
Two healthy looking colonies, M and X, from successful Gibson Assembly colonies
(Section 2.3.3 were purified with a Qiagen Mini-Prep Purification Kit as per
manufacturer instructions. The samples in Table 2.7 were incubated for 1 hour at
37 ◦C before an agarose gel was run and visualised under UV light.
Purified plasmids SaHisGS-pJexpress411-MBP-(construct X) and SaHisGS-pJexpress411-
MBP-(construct M) from successful Gibson Assembly were sent to Eurofins Genomics for
sequencing with the T7 promoter primer (5′-TAATACGACTCACTATAGGG-3′) and an
internal sequencing primer (5′-CAT TTA AAG GCC AGC CTA GCA-3′).
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Table 2.7: Gibson Assembly plasmid purification incubation samples. C is a control













Plasmid X (µL) 5 5 10 0 0 0
Plasmid M (µL) 0 0 0 5 5 10
HindIII (µL) 0 1 1 0 1 1
Nde1 (µL) 0 1 1 0 1 1
Buffer (µL) 2 2 2 2 2 2
Water (µL) 13 11 6 13 11 6
Expression Tests of SaHisGS-pJexpress411-MBP
The expression trials were carried out as outlined in Table 2.8.
Table 2.8: Expression tests of SaHisGS-pJexpress411-MBP.






BL21(DE3) LB 37 0.5 20 Bug Buster
BL21(DE3) LB 37 0.5 44 Bug Buster
BL21(DE3) LB 20 0.5 20 Bug Buster
BL21(DE3) LB 15 0.5 20 Bug Buster
Origami 2 LB 37 0.5 20 Bug Buster
Origami 2 LB 16 0.5 20 Bug Buster
SoluBL21 LB 37 0.5 20 Bug Buster
SoluBL21 LB 37 0.5 44 Bug Buster
SoluBL21 LB 16 0.5 20 Bug Buster
SoluBL21 LB 16 0.5 44 Bug Buster
C43(DE3) LB 16 0.5 20 Bug Buster
Protein Purification and Solubility Trials
Large scale trials (1–2 L of culture) were passed through a HisTrap FF 5 mL nickel column
to determine whether soluble SaHisGS was present in concentrations lower than what
could be discernible by analysis of the crude extract. The conditions listed in Table 2.9
were tested.
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Table 2.9: Large scale protein purification solubility trials with SaHisGS-pJexpress411.
E. coli Strain Media Induction Temp. (◦C) Culture Volume (L) IPTG (mM)
C43(DE3) LB 16 1 0.5
C43(DE3) LB 37 2 0.5
2.3.4 Lysis Buffer Solubility Trials
Tris/Bis Tris Lysis Buffer Screen
Alternative lysis buffers to Bug Buster were screened to determine whether SaHisGS
requires a different reagent for solubility. The expression tests outlined in Table 2.10
were trialled.
Reducing Agent Buffer Trials
β-mercaptoethanol (BMCE) and dithiothreitol (DTT) were tested with original protein
purification buffer (buffer A1) to determine whether they had a stabilising effect on
soluble protein by reducing disulphide bonds. Cultures of SaHisGS-pJexpress411 grown
at 37 ◦C in LB media and induced with 0.5 mM IPTG were used and the lysis buffers
outlined in Table 2.11 were tested. HEPES buffers were adjusted to pH 8.0, Tris buffers
to pH 8.0 and Bis-Tris buffers to pH 6.8.
SaHisGS Protein Purification Trial with DTT in Buffer
Large scale trial (4 L of C43(DE3) culture) was passed through a HisTrap Excel FF 5
mL nickel column using buffers containing DTT to stabilise soluble SaHisGS . Line A
contained 50 mM HEPES, 150 mM NaCl, 10 mM Imidazole, 4mM DTT and Line B
contained 50 mM HEPES, 150 mM NaCl, 500 mM Imidazole, 4 mM DTT.
SaHisGS Lysis Buffer Trial with SaHisZ in Buffer
SaHisZ was tested with the original protein purification buffer to determine whether
SaHisZ has a stabilising effect on soluble protein. Expression tests of SaHisGS-
pJexpress411 grown at 37 ◦C in LB media and induced with 0.5 mM IPTG were used
and the lysis buffers outlined in Table 2.12 were tested (in addition, all contained 150
mM NaCl).
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Table 2.10: Tris and Bis-Tris lysis buffer expression tests with SaHisGS-pJexpress411.
with SaHisGS-pJexpress411.
E. coli Strain Medium
Expression
Temp ◦C
[ITPG] (mM) Lysis Buffer
C43 (DE3) LB 37 0.5 20 mM Bis Tris, 150 mM NaCl
C43 (DE3) LB 37 0.5 20 mM Bis Tris, 500 mM NaCl
C43 (DE3) LB 37 0.5 20 mM Bis Tris, 150 mM
NaCl, 100 mM Arginine
C43 (DE3) LB 37 0.5 20 mM Bis Tris, 150 mM
NaCl, 100 mM Glycine
C43 (DE3) LB 37 0.5 20 mM Bis Tris, 150 mM
NaCl, 0.1% v/v Igepal
C43 (DE3) LB 37 0.5 20 mM Bis Tris, 150 mM
NaCl, 0.1% v/v Triton X100
C43 (DE3) LB 37 0.5 20 mM Bis Tris, 150
mM NaCl, 10 mM β-
mercaptoethanol
C43 (DE3) LB 37 0.5 20 mM Tris, 150 mM NaCl
C43 (DE3) LB 37 0.5 20 mM Tris, 500 mM NaCl
C43 (DE3) LB 37 0.5 20 mM Tris, 150 mM NaCl,
100 mM Arginine
C43 (DE3) LB 37 0.5 20 mM Tris, 150 mM NaCl,
100 mM Glycine
C43 (DE3) LB 37 0.5 20 mM Tris, 150 mM NaCl,
0.1% v/v Igepal
C43 (DE3) LB 37 0.5 20 mM Tris, 150 mM NaCl,
0.1% v/v Triton X100
C43 (DE3) LB 37 0.5 20 mM Tris, 150 mM NaCl, 10
mM β-mercaptoethanol
C43 (DE3) LB 37 0.5 20 mM Tris, 150 mM NaCl, 8
µM SaHisZ
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Imidazole (mM) Histidine (mM)
1 50 - 10 - - -
2 50 500 10 - 10 -
3 50 500 - 4 10 -
4 50 500 - - 10 -
5 50 - - 4 - -
6 50 500 10 - - -
7 50 150 10 - 10 -
8 75 - - 6 - -
9 75 225 - 6 - -
10 75 - - 6 15 -
11 75 225 - 6 15 -
12 75 - - 6 - 15
13 75 - - 6 - 15










Imidazole (mM) Histidine (mM)
1 20 - 8 - - -
2 20 - 8 - 10 -
3 - 50 8 - - -
4 - 50 8 - 10 -
5 - 50 8 4 - -
6 - 50 8 - - 10
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Co-purification of SaHisGS with SaHisZ (inc. Glass beads)
Three protein purifications utilising co-purification with SaHisZ were carried out as in
Section 2.2.5 but with 50:50 SaHisZ and SaHisGS cell pellets used. Two trials with low
salt were trialled, either with 150 mM NaCl or 150 mM KCl in Buffers A and B instead
of 500 mM NaCl. An additional trial using glass beads to lyse the cells instead of an
emulsifier was undertaken. For glass bead lysis, cells pellets were prepared in the same
way as when using the emulsifier, but instead of passing through the cell disrupter, the
cell pellets were shaken overnight at 4 ◦C with 1 ml of 0.5 mm diameter small glass
beads. Due to the longer lysis period, one whole tablet of EDTA free protease inhibitor
cocktail (Cφmplete) was used along with a reduction in lysozyme (0.01 mg/ml).
2.4 Expression of PaHisGS and PaHisZ
PaHisGS-pJ411express plasmid was transformed into E. coli C43(DE3) competent
cells (Sigma-Aldrich) and PaHisZ-pJ434express plasmid was transformed into E. coli
BL21(DE3) competent cells (Novagen). Transformed cells were grown and induced as in
Section 2.2.2 at 16 ◦C.
PaHisGS and PaHisZ (tagged and un-tagged) were purified separately from respective
cell pellets with all steps carried out at 4 ◦C and utilising an AKTA Start FPLC system
(GE Lifesciences) for the chromatographic procedures. The final concentrations of
PaHisGS and PaHisZ were determined spectrophotometrically using a NanoDrop at 280
nm with theoretical extinction coefficients (ε280) of 8940 M−1 cm−1 and 25900 M−1 cm−1,
respectively for untagged protein and 10430 M−1 cm−1 and 27390 M−1 cm−1, respectively
for tagged protein. The molecular masses of 25213 Da (PaHisGS ) and 43085 Da (PaHisZ)
were verified by ESI-MS.
2.4.1 Purification of PaHisGS and PaHisZ
The purification of PaHisGS and PaHisZ were carried out exactly as in Stroek et
al. [20]. A HisTrap FF 5 mL column with a linear 0–300 mM imidazole gradient
was used to remove contaminant proteins by fractionation before and after cleavage
of the 6xHis-tag by TEVP. Fractions were analysed by sodium dodecyl sulfate−
polyacrylamide gel electrophoresis (SDS−PAGE) (NuPAGE Bis-Tris 4–12% Precast gels,
Thermo Fisher Scientific) and concentrated using 10000 molecular weight cut off
(MWCO) ultrafiltration membranes (Millipore). Both proteins were stored in 20 mM
HEPES (pH 8.0) at −80 ◦C.
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2.4.2 Method Development of Large Scale PaHisZ Purification
A larger scale purification of PaHisZ was trialled with cell pellets from 5 L of cell culture
and a larger HisTrap FF 20 mL column. Cells were thawed on ice for 30 min before being
resuspended in Buffer A [50 mM HEPES, 10 mM imidazole, and 500 mM NaCl (pH
8.0)] containing 0.2 mg/mL lysozyme, 0.05 mg/mL DNase I, and one tablet of EDTA-
free Cømplete protease inhibitor cocktail. Cells were disrupted in a high-pressure cell
disruptor and centrifuged at 48000 g for 30 min to remove cell debris. The supernatant
was filtered through a 0.45 µm membrane and loaded onto a HisTrap FF 20 mL column
pre-equilibrated with Buffer A. The column was washed with 15 CV of Buffer A and the
adsorbed proteins were eluted with 20 CV of a linear gradient from 0–40% Buffer B [50
mM HEPES, 500 mM imidazole, and 500 mM NaCl (pH 8.0)]. Fractions containing the
desired protein were initially pooled and concentrated using repeated cycles of a 10000
MWCO centrifugal filter unit (Amicon) and centrifuge (5000 g, 15 min) before using a
30000 MWCO ultrafiltration membrane. The sample was dialysed overnight in 30000
MWCO dialysis cassettes against 2 times 2 L of 20 mM HEPES (pH 8.0) followed by 2 L
of 20 mM HEPES (pH 7.5) before adding 10 mg of TEVP and dialyzed twice against 2
L of Dialysis Buffer 1. This was repeated for two further additions 10 mg of TEVP and
then dialysed against 2 L of Buffer A. Sample was centrifuged (48000 g, 30 min) then
filtered through 0.45 µm membranes and loaded onto a HisTrap FF 20 mL column pre-
equilibrated with buffer A. The flow through was collected and analyzed by SDS−PAGE,
concentrated using 30000 MWCO ultrafiltration membranes, dialyzed 3 times against 2
L of 20 mM HEPES (pH 8.0). A second round of TEVP cleavage was carried out with 7
mg TEVP for 5 days before dialyzing twice against 2 L of Buffer A. Sample filtered once
more through 0.45 µm membranes and loaded onto a HisTrap FF 20 mL column pre-
equilibrated with Buffer A and using same method as previously. Fractions containing
PaHisZ were pooled, concentrated as previously, aliquoted and stored at −80 ◦C.
2.4.3 Purification of 6HPaHisGS and 6HPaHisZ
Cells were thawed on ice for 20 min before being resuspended in Buffer A containing
0.2 mg/mL lysozyme, 0.05 mg/mL DNase I, and one half-tablet of EDTA-free Cømplete
protease inhibitor cocktail. Cells were disrupted in a high-pressure cell disruptor
and centrifuged at 48000 g for 30 min to remove cell debris. The supernatants were
filtered through a 0.45 µm membrane and loaded onto a HisTrap FF 5 mL column
pre-equilibrated with Buffer A. The column was washed with 10 CV of Buffer A
and the adsorbed proteins were eluted with 20 CV of a linear gradient from 0 to
60% Buffer B. Fractions containing the desired protein with no visible contaminant
proteins were pooled and dialyzed twice against 2 L of 20 mM HEPES (pH 8.0) before
being concentrated using a 10000 molecular MWCO or 30000 MWCO ultrafiltration
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membrane (Millipore) for 6HPaHisGS and 6HPaHisZ respectively. The samples were
aliquoted and stored at −80 ◦C.
2.5 Differential Scanning Fluorimetry-based Thermal Shift
Assay
2.5.1 DSF-based Thermal Shift Assay of Histidine Binding to PaHisZ
Differential scanning fluorimetry-based (DSF) thermal shift assay was performed as
previously described [115] at λex = 490 nm and λem = 610 nm in 96-well plates on
a Stratagene Mx3005p instrument. The assay of histidine binding to PaHisZ was
performed from 25–65 ◦C in 1 ◦C/min increments in quintuplicate with 9.4 µM PaHisZ
in Kinetic Buffer [100 mM Tricine, 15 mM MgCl2, 100 mM KCl, 4 mM DTT] and 0–8
mM histidine. Sypro Orange (5×) (Invitrogen) was added to all wells. The Tm of each
sample was determined as previously described [115] with control curves (no enzyme)
subtracted from curves containing enzyme. Equation 2.1 was used and the data analysed
by the nonlinear regression function of SigmaPlot 13 (SPSS Inc.). FU is fraction unfolded,
T is the temperature in ◦C, Tm is the melting temperature, c is the slope of the transition
region, and LL and UL are folded and unfolded baselines, respectively. The results were
plotted against [histidine] to determine the KD with respect to PaHisZ using SigmaPlot







2.5.2 DSF-based Thermal Shift Assay of PRPP Binding to PaHisGS
Differential scanning fluorimetry-based thermal shift assay was performed as previously
described [115]. The assay for PRPP binding to PaHisGS was performed from 25–70 ◦C
(with a 1 ◦C/min increase) in quintuplicate with 10 µM PaHisGS in Kinetic Buffer [100
mM Tricine, 15 mM MgCl2, 100 mM KCl, 4 mM DTT] and 0–2 mM PRPP. The fraction of
protein unfolded at each temperature was determined as described in Section 2.5.1 using
Equation 2.1 and compared between two different batches of PaHisGS .
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2.6 Kinetic Methods
Unless otherwise stated all kinetic methods were carried out using 5x Kinetic Buffer
Stock Solution (500 mM Tricine, 75 mM MgCl2, 500 mM KCl, 20 mM DTT, 10 µM
pyrophosphatase, pH 8.5) to give a final concentration of Kinetic Buffer of 100 mM
Tricine, 15 mM MgCl2, 100 mM KCl, 4 mM DTT and 2 µM pyrophosphatase (MtPPase).
An UV-2600 spectrophotometer outfitted with a CPS unit for temperature control was
used unless stated otherwise. PRATP formation was monitored continuously at 290 nm
(ε290 = 3600 M−1 cm−1 at pH 8.5) at 20 ◦C in 1-cm path length quartz cuvettes. Rate of
absorbance change was transformed into rate of PRATP formation using Equation 2.2.
The standard error was calculated for all readings using Equation 2.3 where n is the
number of replicates recorded. Control reactions lacked either ATP, PRPP, PaHisGS , or

















2.6.1 Determination of KD values
The dissociation constant (KD ) values for the PaHisGS and PaHisZ subunits of PaATPPRT
were determined by using 0.67 µM HisG and monitoring the rate of PRATP formation
from 0–18.4 µM PaHisZ.
The KDvalue for the PaHisGS and PaHisZ subunits of 6HPaATPPRT were determined
by using 0.17 µM PaHisGS and monitoring the rate of PRATP formation from 0–19 µM
PaHisZ.
The KD was calculated by fitting to the Morrison Equation (Equation 2.4) [116] where E
is equal to [PaHisGS ], S is equal to [PaHisZ]. And Vmax is the maximal rate of the system.
v = Vmax
(E + S +KD )−
√





2.6.2 Determination of KM values
The KM values with respect to each substrate (ATP or ADP and PRPP) were determined
by varying the concentration of one substrate while fixing the other substrate
concentration at saturating levels (see Table 2.13).
Table 2.13: Assay concentrations of substrates used for determining KM values.






KMAT P PaATPPRT 0.28 0.4–5.6 - 2
KMPRP P PaATPPRT 0.28 5.6 0.1–2
KMPRP P PaATPPRT 0.28 - 5.6 0.1–4
KMADP PaATPPRT 0.28 - 0.4–5.6 2
KMAT P 6HPaATPPRT 0.16 0.2 - 1.2 - 2
KMPRP P 6HPaATPPRT 0.16 5.6 - 0.03–4
The KM was calculated using Equation 2.5 if no substrate inhibition was observed, or
if it was, either Equation 2.6 (standard substrate inhibition) or Equation 2.7 (Haldane
substrate inhibition [117]) where v is the initial rate, E is the concentration of enzyme,
kcat is the steady-state turnover number, S is the substrate concentration, KM is the























2.6.3 Determination of IC50 values
The inhibitor IC50 values for histidine and AMP with respect to PaATPPRT were
determined by monitoring the rate of PRATP formation with varying concentrations of
each inhibitor and fixed enzyme and substrate concentrations (see Table 2.14).
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Table 2.14: Assay concentration of inhibitors, enzyme and substrates used for
determining IC50 values.






PaATPPRT Histidine 0.24 0–320 5.6 - 2
PaATPPRT Histidine 0.28 0–320 - 5.6 2
6HPaATPPRT Histidine 0.16 0–640 5.6 - 2
PaATPPRT AMP 0.14 0–2400 5.6 - 2
PaHisGS AMP 4.5 0–800 5.6 - 2
PaHisGS ITP 4.5 0–800 5.6 - 2
The IC50 value is calculated using Equation 2.8 where vo and vi are the rates in the
absence and presence of inhibitor, respectively, I is the concentration of inhibitor and










2.6.4 Determination of Kivalues
Determination of Ki values for histidine and AMP were carried out by monitoring the
rate of PRATP formation across a range of substrate concentrations at fixed inhibitor
concentrations (see Table 2.15). Ki values were obtained by fitting globally to a 3D
hyperbola for initial rate (v), I and S (inhibitor and substrate concentration, respectively).
The resulting lines of best fit were fitted to one of Equation 2.9 (competitive inhibition),
Equation 2.10 (non-competitive inhibition) or Equation 2.11 (uncompetitive inhibition)
to determine which model for inhibition best fits te data. S is the substrate concentration,
E is the enzyme concentration, Kii is the Ki intercept and Kis is the Ki slope, kcat is
the steady-state turnover number, KM is the Michaelis constant and Ki is the inhibitor

















































Inhibitor [E] (µM) [I] (µM) [ATP] (mM) [PRPP] (mM)
PaATPPRT PRPP Histidine 0.28 0–20 2.8 0.1–2
PaATPPRT ATP Histidine 0.28 0–20 0.4–5.6 2
PaHisGS ATP AMP 4.5 0–250 0.4–5.6 2
PaHisGS PRPP AMP 4.5 0–50 5.6 0.1–2
PaATPPRT ATP AMP 0.29 0–400 0.4–5.6 2
PaATPPRT PRPP AMP 0.29 0–200 5.6 0.1–2
2.6.5 PaHisGS Mutant Sensitivity to Histidine
In order to determine whether PaHisGS mutants C115S and R56A are as sensitive to
histidine as the WT, the rate of PRATP formation was monitored using 4.7 µM PaATPPRT
(either WT, C115S or R56A PaHisGS complexed with WT PaHisZ) with 0 µM or 640 µM
histidine. The rate of PRATP formation by the mutants were compared to WT data and
normalised against 0 µM histidine.
2.6.6 Effect of ITP, CTP and R5P on PaHisGS
To determine whether ITP (inosine triphosphate) influences PaHisGS , the rate of PRATP
formation was monitored using 4.5 µM PaHisGS with 0–6 mM ITP in the standard assay
conditions of 5.6 mM ATP and 2 mM PRPP.
To determine whether CTP (cytidine triphosphate) influences PaHisGS , the rate of
PRATP formation was monitored using 4.5 µM PaHisGS with 0 or 2.4 mM CTP. Due to
the absorbance of CTP, smaller path length (0.5 cm) cuvettes were used with 2 mM ATP
and 4 mM PRPP.
To determine whether ribose-5-phosphate (R5P) influences PaHisGS , the rate of PRATP
formation was monitored using 4.5 µM PaHisGS with 0–2.4 mM R5P in the standard
assay conditions of 5.6 mM ATP and 2 mM PRPP.
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2.6.7 Effect of 3-(2-thienyl)-L-alanine on PaATPPRT
To determine whether 3-(2-thienyl)-L-alanine (TIH) influences PaATPPRT the rate of
PRATP formation was monitored using 0.29 µM PaATPPRT with 0 or 4 mM TIH under
the standard assay conditions.
2.6.8 Effect of dATP as an Alternative Substrate
To determine whether dATP is an alternative substrate for PaHisGS the formation of
PRATP was monitored for assays of 4.5 µM PaHisGS with 0–5.6 mM dATP (instead of
ATP) as the substrate and 2 mM PRPP.
2.6.9 Effect of buffer pH on PaHisGS Activity
To determine whether PaHisGS activity was effected by an unexpected error in pH
preparation of the buffer, rate of absorbance change was monitored for an assay of 7.5
µM PaHisGS , 2 µM PRPP and 5.6 mM ATP with Kinetic Buffer [100 mM Tricine, 15 mM
MgCl2, 100 mM KCl, 4 mM DTT, 2 µM PPase] at pH 8.1–8.8. ε290 = 3100 M−1 cm−1 at
pH 8.0, 3600 M−1 cm−1 at pH 8.5 and 4000 M−1 cm−1 at pH 9.5. This was repeated for a
second, more active, batch, of PaHisGS (2 µM).
2.6.10 Rapid kinetics of PaHisGS and PaATPPRT Reaction with Histidine
Present
Using an SX-20 stopped-flow spectrophotometer (0.9-ms deadtime), syringe A (2.4 µM -
4.2 µM PaHisGS or 3.98 µM PaATPPRT, 0–1280 µM histidine, 4 mM PRPP, 8 mM DTT,
4 µM PPase, 100 mM Tricine, 15 mM MgCl2, 100 mM KCl, pH 8.5) was rapidly mixed
with syringe B (11.2 mM ATP, 100 mM Tricine, 15 mM MgCl2, 100 mM KCl, pH 8.5) in a
0.5-cm mixing cell in quadruplicate traces. Final concentrations in the mixing cells were
1.2 µM - 2.1 µM PaHisGS or 1.99 µM PaATPPRT, 0–640 µM histidine, 2 mM PRPP, 5.6
mM ATP, 4 mM DTT, 2 µM PPase, 100 mM Tricine, 15 mM MgCl2, 100 mM KCl. The
time course of PRATP formation was monitored for 10 s. The rate of PRATP formation
with and without histidine was compared between PaHisGS and PaATPPRT. A t-test was
performed to confirm statistical significance.
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2.6.11 Effect of Histidine on the Approach to Steady State
Using an SX-20 stopped-flow spectrophotometer, 55 µL of syringe A (4 µM PaATPPRT,
0 or 1280 µM histidine, 4 mM PRPP, 4 mM DTT, 10 µM MtPPase, 100 mM Tricine, 15
mM MgCl2, 100 mM KCl, pH 8.5) was rapidly mixed with 55 µL of syringe B (11.2 mM
ATP, 4 mM DTT, 10 µM PPase, 100 mM Tricine, 75 mM MgCl2, 100 mM KCl, pH 8.5) in
a 5 µL mixing cell, in quadruplicate. Final concentrations in the mixing cells were 2 µM
PaATPPRT, 0 or 640 µM histidine, 2 mM PRPP, 5.6 mM ATP, 4 mM DTT, 10 µM MtPPase,
100 mM Tricine, 15 mM MgCl2, 100 mM KCl. The time course of PRATP formation was
monitored for 10 s. The rate of PRATP formation was monitored by absorbance increase
in a linear-time base for 10 s with 1000 data points collected per trace. Rates with and
without histidine were compared. Controls lacked PRPP.
2.6.12 Approach to Steady State in the Presence of Histidine
Using an SX-20 stopped flow spectrophotometer, 55 µL of syringe A (38 µM PaATPPRT,
0 or 60 µM histidine, 4 mM PRPP, 4 mM DTT, 10 µM MtPPase, 100 mM Tricine, 15 mM
MgCl2, 100 mM KCl, pH 8.5) was rapidly mixed with 55 µL of syringe B (0 or 60 µM
histidine, 7 mM ATP, 4 mM DTT, 10 µM PPase, 100 mM Tricine, 75 mM MgCl2, 100 mM
KCl, pH 8.5) in a 5 µL mixing cell, in quadruplicate. Final concentration in the mixing
cell were 19 µM PaATPPRT, 0 or 30 µM histidine, 2 mM PRPP, 3.5 mM ATP, 4 mM
DTT, 10 µM MtPPase, 100 mM Tricine, 15 mM MgCl2, 100 mM KCl. Controls lacked
PRPP. The time course of PRATP formation was monitored by absorbance increase in a
split-time base for 1 s, with 2500 data points collected before 0.2 s and 2500 data points
in the following 0.8 s. The rate of PRATP formation with and without histidine was
compared between PaHisGS and PaATPPRT.
2.7 Crystallography
2.7.1 Crystallisation Trials of PaATPPRT:Histidine
Crystallisation trials for histidine bound to the hetero-octameric complex were based
upon previously successful crystallization trials of PaATPPRT [20]. All steps were
carried out at 4 ◦C. PaHisGS and PaHisZ were mixed in 1:1 molar ratio and incubated
with 10 mM Mg-ATP overnight. The buffer was exchanged with Crystallisation Buffer
[20 mM Tris (pH 7.0), 50 mM KCl, 10 mM MgCl2, 2 mM DTT, 0.5 mM histidine] and
concentrated using an 10,000 MWCO centrifugal filter unit to ∼ 8 mg/ml before 0.5 µL
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Mg-ATP per 50 µL of protein was supplemented in.
Crystal trials were set up using the hanging-drop vapour-diffusion method in 24-well
plates with 500 µL Reservoir Buffer [11% polyethylene glycol (PEG) 3350, 100 mM bicine
(pH 8.5), 150 mM SrCl2, 150 mM KBr, 2% 1,6-hexanediol] in the reservoir. Drops were
comprised of 1 µL protein solution and 1 µL Reservoir Buffer with or without 0.2 µL
1:500 seed stock. Crystals were left to grow for 21 days at 4 ◦C.
2.7.2 Soaking Trials of Substrate and Histidine into PaATPPRT Crystals
Three crystals were washed in Soaking Buffer 1 [10% PEG 3350, 0.1 M bicine pH 8.5, 50
mM MgCl2, 0.1 M KBr, and 4% 1,6-hexanediol] before being transferred to a series of
droplets containing soaking buffer, substrate and histidine. Solid particles of ATP, PRPP
and histidine were added to Soaking Buffer 1 to create Soaking Buffer 2 [ATP and PRPP]
and Soaking Buffer 3 [ATP, PRPP and histidine].
Crystals were soaked in Soaking Buffer 1 for 1 min, which was then followed by soaking
in Buffers 2 and 3 for 3, 30 or 60 min each. A fourth trial was set up where the crystal was
soaked for 10 min in Soaking Buffer 2 and 20 s in Soaking Buffer 3. Soaking in Buffers
1-3 was always followed by 10 s soak in cryoprotectant [20% 2-methyl-2,4-pentanediol
(MPD), 80 % Soaking Buffer 1 (v/v)] and then flash frozen in liquid nitrogen at -196 ◦C.
2.7.3 X-ray Data Collection and Processing
Crystals were tested in-house for X-ray diffraction and the data were collected on a
Rigaku 007 MM HFM generator with a Saturn 944+ CCD detector. Crystals that
diffracted less than 5 A in-house were sent for data collection at beamline i24 at the
Diamond Light Source (Oxfordshire, UK). The diffraction data was processed using the
automated processing pipeline integrated with XDS [118] and scaled using AIMLESS
[119]. The structure of good quality diffraction data were solved with MOLREP [120]
using PDB 6FTT [101] as a search model. The model was refined using cycles of model-




3.1 Expression and Purification of SaATPPRT
Initially the ATPPRT from S. aureus was sought for study. In addition to the rational
presented in Section 1.2 for studying ATPPRTs (advancement in biotechnology and as
a model for allostery and A. baumannii drug discovery), study of S. aureus ATPPRT
provided an additional advantage. S. aureus is one of the leading bacterial pathogens
in hospital-acquired infections [123], with around half of these strains being resistant
to commonly prescribed antibiotics [124] and some resistant to all available antibiotics
[125]. As such, new antibiotics for S. aureus are desperately needed. It was originally
hoped that study of S. aureus ATPPRT in particular, could directly lead to a viable drug
target as the histidine pathway is not present in humans and so side effects would be
minimized. Although there were no knock-out studies published for S. aureus proving
the gene essential to infection or virulence, there was evidence from flux balance analysis
by Henriksen et.al [126] stating that inhibition of any histidine pathway step would halt
histidine production. Therefore, purification of SaATPPRT was trialled first.
3.1.1 SaHisZ Expression and Purification
Over-expression of S. aureus protein SaHisZ (33460 Da with 6xHis-tag) occurred at both
temperatures trialled (Figure 3.1), 37 ◦C and 16 ◦C. The protein mainly expressed in the
insoluble fraction at 37 ◦C (Figure 3.1, lane 12). There was a small band present at the
correct height for SaHisZ in the soluble fraction (Figure 3.1, lane 11) but it is unclear
whether this was a small expression of SaHisZ or a contaminant protein. However,
there is clear over-expression of SaHisZ in the soluble fraction when induced at 16 ◦C
with 0.5 mM IPTG Figure 3.1, lane 15). If protein is present in the soluble fraction it
suggests that the protein has been folded correctly by the expression system and further
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purification of the protein is possible. Lowering the temperature and the concentration
of IPTG can often lead to increased soluble expression of protein because there is more
time for protein folding due to slower expression. Additionally, high concentrations of
IPTG can significantly reduce growth of recombinant E. coli cells and hence protein yield
[127].
Figure 3.1: SDS-PAGE of SaHisZ and SaHisGS cell lysate from small scale expression
tests of temperature and IPTG concentation. Odd lane numbers are soluble fractions
and even lane numbers are insoluble fractions. SaHisGS expression tests are in lanes
1–8 and SaHisZ in lanes 9-16. Lanes 1–4 and 9–12 were expression tests carried out
at 37 ◦C and lanes 5–8 and 13–16 at 16 ◦C. Lanes 1–12 used 1 mM IPTG and lanes
13–16 used 0.5 mM IPTG expression conditions. Lanes 1–2, 5–6, 9–10 and 13–14 were
control samples pre-induction and lanes 3-4, 7-8, 11–12 and 15–16 were samples post-
induction. Lane (L), enzyme (E), temperature (T), sample type (s), test sample (S), control
sample (C). Molecular weight ladders are present in unmarked lanes with size label
below corresponding protein band.
A large-scale purification and TEVP cleavage of SaHisZ using 16 ◦C and 0.5 mM
expression conditions was trialled. The initial nickel column was successful with a large
amount of SaHisZ accounted for on the gel (Figure 3.2, A). Unfortunately, the TEVP
cleavage suffered from extensive crashing out of protein. Upon SDS-PAGE analysis it
was determined that TEVP had crashed out and SaHisZ remained in solution. Therefore,
after filtering and re-cleaving, a second nickel column was run. Although some SaHisZ
was present in the wash, the majority was found in the imidazole gradient factions
(Figure 3.2, B). This suggested that either, SaHisZ had not fully cleaved (unlikely given
SDS-PAGE showed a less intense band compared to uncleaved sample) or that SaHisZ
has some affinity to the column without the 6xHis-tag. A third nickel column using
loading and wash buffer with 10 mM imidazole resulted in SaHisZ eluting in the wash.
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This confirms that the 6xHis-tag had now been successfully removed and that untagged
SaHisZ does have some affinity for the nickel column once the 6xHis-tag has been
removed. However, there were still trace amounts of protein at lower molecular weight
than SaHisZ present in the protein solution. Gel filtration produced one clean peak
but SDS-PAGE (Figure 3.3) of the resulting fractions highlighted lower molecular weight
protein bands were still present. Mass spectrometry and a Mascot protein search of the
NCBI database confirmed the extra bands to be SaHisZ. This is likely to be an artefact of
the gel rather than degradation products as the samples were re-run and no additional
bands were present. Furthermore, the intact mass was 31710.4 Da by ESI-MS, matching
the actual mass of cleaved SaHisZ protein (31710.9 Da).
Figure 3.2: FPLC elution profile of SaHisZ nickel column purification steps from A) pre-
TEVP cleavage and B) post-TEVP cleavage.
Despite initial method setbacks, 72 mg of SaHisZ was successfully purified. There was
clear scope to improve the method for subsequent purifications but no further batches of
SaHisZ were ever required.
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Figure 3.3: SDS-PAGE after final SaHisZ purification step (untagged). Molecular weight
ladder is present in left hand lane with size label immediately below corresponding
protein band.
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3.1.2 SaHisGS Expression and Purification
All expression attempts from this section are summarised in Table 3.1.
Temperature and IPTG Concentration
Over-expression of S. aureus protein SaHisGS (24403 Da with 6xHis-tag) was successful
with 1 mM IPTG at both temperatures, 37 ◦C and 16 ◦C (Figure 3.1) but expressed in the
insoluble fraction of the cell lysate. Upon successful soluble over-expression of SaHisZ
when IPTG concentration was lowered, expression trials with 0.5 mM and 0.1 mM IPTG
were set-up for SaHisGS . Unfortunately, although there was more over-expression with
0.5 mM IPTG than 1 mM or 0.1 mM IPTG, the protein remained insoluble for all IPTG
concentrations at 37 ◦C and 16◦C.
Alternative Strains
Given that temperature and IPTG concentration changes had not resulted in soluble
SaHisGS in BL21(DE3), alternative strains were considered. Using C43 (DE3) cells, a
strain specifically engineered for recombinant proteins which may be toxic to BL21(DE3)
cells [112], over-expression of SaHisGS was successful at 0.5 mM and 0.1 mM IPTG at 37
◦C but all SaHisGS resided in the insoluble fraction (Figure 3.4 A). No over-expression
was found in C43 (DE3) at 16◦C at either concentration of IPTG. Using Origami 2(DE3)
cells, a strain with additional folding apparatus [113], SaHisGS over-expressed at both
temperatures and 0.1 mM and 0.5 mM of IPTG but all over-expressed protein was
insoluble (Figure 3.4 C). The outcome was the same for BL21Gold(DE3) cells (not
shown). These cells are superior strains of BL21(DE3) with two proteases capable
of degrading recombinant protein removed [114]. Despite being insoluble, the best
over-expression was achieved using BL21(DE3) and C43 (DE3). Another strain with
advantages for leaky expression of toxic proteins was tested, BL21GoldPlysS(DE3)[314],
but no expression was found, except at 37◦C where the protein was insoluble (not
shown).
It was hoped that SoluBL21 could help solubilise SaHisGS since the strain is specifically
optimised for this purpose [128]. Unfortunately, no over-expression of SaHisGS was
identified using SoluBL21 cells at 37 ◦C or 16 ◦C (Figure 3.4 B), even with an additional
24 hour growth period after induction (0.5 mM IPTG).
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Table 3.1: Summary of SaHisG-pJexpress411 expression results from different
temperatures, IPTG concentrations, E. coli strains and media. BLGold refers to the strain










BL21(DE3) LB 37 1 Bug Buster 3 5
BL21(DE3) LB 16 1 Bug Buster 3 5
BL21(DE3) LB 37 0.5 Bug Buster 3 5
BL21(DE3) LB 16 0.5 Bug Buster 3 5
BL21(DE3) LB 37 0.1 Bug Buster 3 5
BL21(DE3) LB 16 0.1 Bug Buster 3 5
C43 (DE3) LB 37 0.5 Bug Buster 3 5
C43 (DE3) LB 16 0.1 Bug Buster 5 5
C43 (DE3) LB 37 0.5 Bug Buster 3 5
C43 (DE3) LB 16 0.1 Bug Buster 5 5
Origami 2 LB 37 0.5 Bug Buster 3 5
Origami 2 LB 16 0.1 Bug Buster 3 5
Origami 2 LB 37 0.5 Bug Buster 3 5
Origami 2 LB 16 0.1 Bug Buster 3 5
SoluBL21 LB 37 0.5 Bug Buster 5 5
SoluBL21 LB 16 0.5 Bug Buster 5 5
BLGold LB 37 0.5 Bug Buster 3 5
BLGold LB 16 0.5 Bug Buster 3 5
BLGold LB 37 0.1 Bug Buster 3 5
BLGold LB 16 0.1 Bug Buster 3 5
BLGoldplysS LB 37 0.5 Bug Buster 3 5
BLGoldplysS LB 16 0.5 Bug Buster 5 5
C43 (DE3) TB 37 0.5 Bug Buster 3 5
C43 (DE3) TB 16 0.5 Bug Buster 3 5
C43 (DE3) TPB 37 0.5 Bug Buster 3 5
C43 (DE3) TPB 16 0.5 Bug Buster 3 5
C43 (DE3) LB & Mg2+ 37 0.5 Bug Buster 3 5
BL21(DE3) Auto-ind. 16 N/A Bug Buster 3 5
BL21(DE3) Auto-ind. 16 N/A Emulsifier 3 5
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Figure 3.4: SDS-PAGE of SaHisGS cell lysate from small scale expression tests of strains
(A) C43(DE3) (B) SoluBL21 (C) Origami 2(DE3) and (D) TPB and TB media. Lanes
(L) are numbered with temperature (T), IPTG concentration (I), media (M) and sample
type (s), either control (C) or experimental sample (S) are indicated below each figure.
Odd lane numbers are from soluble fractions and even lane numbers are from insoluble




Over-expression of SaHisGS was only observed at 37◦C for TPB and TB and only in
insoluble form (Figure 3.4 B). Previous work by Yang et. al.[129] showed that adding
magnesium ions to the media can increase solubility by 50 %. However, adding
magnesium into LB at 37◦C did not improve target protein solubility in this case.
Auto-induction
Figure 3.5: SDS-PAGE of SaHisZ and SaHisGS cell lysate from auto-induction expression
tests. Odd lane numbers are soluble fractions and even lane numbers are insoluble
fractions. SaHisGS expression tests are in lanes 7-8 and 11-12 and SaHisZ expression
tests are in lanes 5-6 and 9-10. Lanes 5-8 used Bug Buster as the cell lysis method whereas
lanes 9-12 used an emulsifier. Lane (L), enzyme (E), lysis type (Ly). Molecular weight
ladders are present in unmarked lanes with size label below corresponding protein band.
Note there are no control samples due to the nature of the method. Lanes 1-4 correspond
to lanes 13-16 in Figure 3.1
.
An auto-induction method was tested with SaHisGS and the resulting cell pellet lysed
with either Bug Buster or by a high-pressure cell disruptor (emulsification). It was hoped
the cell disruptor would aid solubilisation by breaking up any inclusion bodies that may
have formed. SaHisGS over-expressed using the auto-induction method but remained
insoluble by both the Bug Buster and the emulsification methods (Figure 3.5). An auto-
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induction method was also tested with SaHisZ and although some soluble protein was
obtained it was not an improvement upon the original expression conditions in Section
3.1.1.
3.1.3 SaHisGS-pJexpress411 Plasmid Engineering
Figure 3.6: SaHisGS-MBP-pJ411 plasmid map. Restriction sites are shown in bold and
primer regions used for cloning and sequencing are in purple text. KanR (green box)
denotes the region containing a gene for kanamycin resistance and lacI (maroon box),
the lacI gene. ORI (yellow box) is the origin of replication. SaHisG gene is shown in
the blue box and the MBP gene in the pink box. The G-Block that was inserted into the
plasmid during cloning is shown in the grey box. Image was obtained from SnapGene
software.
As a technique to improve SaHisGS solubility, maltose binding protein (MBP), a
particularly soluble protein [130], was inserted into the SaHisGS-pJ411 plasmid between
the 6xHis-tag and TEV cleavage site (see Figure 3.6) using the Gibson Assembly method.
Initially, PCR was used to amplify linearized fragments of the original SaHisGS-pJ411
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plasmid from Primer 1 anti-clockwise to Primer 2 (can be visualised using Figure 3.6).
After the PCR, Dpn1 (which only cleaves when its recognition site is methylated) was
used to remove any unamplified parent plasmid. Gibson Assembly was used to insert a
G-Block fragment (IDT) containing the MBP gene into the linearized plasmid. Gibson
assembly uses a T5 exonuclease to chew back the PCR fragment and G-block ends.
Complementary fragments anneal and a DNA polymerase completes the strands. Finally,
a DNA ligase seals the nicks and the plasmid cloning is complete. It was hoped that MBP
would increase the overall solubility of the protein and bring SaHisGS into the soluble
fraction. The MBP would then be cleaved off along with the 6xHis-tag during dialysis
with TEVP. There is a risk that SaHisGS would be dragged into the soluble fraction
by MBP and remain insoluble upon TEVP cleavage, but others [131, 132] have shown
success with this strategy.
PCR to Linearize SaHisGS-pJ411 Fragment
Using primers designed to amplify the region of the plasmid which didn’t contain the
G-Block fragment, PCR was used to linearize the original SaHisGS-pJ411 plasmid.
Of the eight conditions tested, only those containing no DMSO were successful with
bands at ∼4000 bp being present at annealing temperatures of 53.2 ◦C to 55 ◦C (Figure
3.7, red box). This corresponds to the size of the linear plasmid fragment (4039 bp)
expected but the bands were very weak. There was also low bp contaminants present
under these conditions however it is unlikely that they carried the full sequence for
antibiotic resistance and so are unlikely to pose problems during further processing (as
any colonies with those DNA will not grow once transformed). The sample from lane
5 (annealing temperature of 53.2 ◦C and containing DMSO) was selected for the Gibson
Assembly since it had the most intense 4000 bp band on the agarose gel.
Gibson Assembly of Linear SaHisGS-pJ411 with MBP G-Block
Of the two G-Block concentrations tested (5x and 10x), the 10x G-Block condition
produced the most viable colonies after transformation (22 colonies compared to 5
colonies for 5x). This is plausible since the 10x condition has more G-Block fragments
available to insert into the linear plasmid fragments. Overall the small number of viable
colonies is likely a direct result of only a weak band having been present after the PCR.
This suggests that there was only a small amount of linear plasmid fragment available for
the assembly. Additionally, dead end assembly may have occurred with the contaminant
fragments that were also present after the PCR.
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Figure 3.7: Agarose gel of PCR to linearize SaHisG-pJ411. Lanes 7–10 contained DMSO,
lanes 3–5 contained no DMSO. Annealing temperature was 52 ◦C for lanes 10 and 6,
53.2 ◦C for lanes 5 and 9, 54 ◦C for 8 and 4, and 55 ◦C for lanes 2, 3 and 7. Lane 2
was a control lacking DNA polymerase and lane 1 was non-linearized SaHisG-pJ411.
The un-numbered lane is a Thermo Fisher Gene Ruler 1 KB DNA ladder with length
corresponding to those annotated.
Plasmid Purification of Gibson Assembly DNA
If the Gibson Assembly was successful, the purified plasmids would contain a HindIII site
and an NdeI site which after digestion with both of these enzymes, would yield fragments
of 1834 bp and 3941 bp long.
After digestion with HindIII and NdeI both plasmid M and plasmid X produced
fragments ∼4000 bp and ∼1800 bp long (Figure 3.8). This is good initial evidence that the
Gibson Assembly was successful and the MBP gene has been inserted into the SaHisGS-
pJ411 plasmid (exact size 5775 bp). The undigested plasmid band for both plasmids,
however, were at ∼10000 on the gel. Given that there are no other bands on the gel to
account for the rest of the base pairs after digestion, and that there is streaking on the
band it is likely that the band ran higher due to concentrated circular DNA.
Furthermore, the original SaHisGS-pJ411 plasmid was 4599 bp and the fragments
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Figure 3.8: Agarose gel of Gibson Assembly digestion of plasmid with HindIII and NdeI.
Lane 1 is a base pair ladder as labelled, 2 is plasmid X (high concentration digest), 3 is
plasmid X (low concentration digest), 4 is plasmid X with no digestion, 5 is plasmid M
(high conconcentraion digest), 6 is plasmid M (low concentration digest), 7 is plasmid M
with no digestion.
resulting from HindIII and NdeI digestion would be 3940 bp and 659 bp. There is no
evidence of the small 659 bp fragment on the gel and so the fragment bands cannot
merely be from digestion of any reformed or residual parent plasmid. This should not
be possible either due to the DpnI digestion after plasmid linearization which should
remove any parent DNA left after PCR.
3.1.4 Expression Tests of SaHisGS-pJ411-MBP
All expression test arbitrarily began with SaHisGS-MBP-pJ411 Construct X (SaHisGS-
MBP(X) while awaiting sequencing results of both construct X and construct M. The
expected size of SaHisGS-MBP(X) is 67302 Da.
Temperature, IPTG concentration and Induction Time
Despite the soluble MBP protein having been inserted into the SaHisGS-pJ411 plasmid,
no soluble expression was found at 15, 20 or 37 ◦C in BL21(DE3) (Figure 3.9). It
appears the MBP protein is still not capable of overcoming the insolubility of SaHisGS
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in BL21(DE3), even if the post-induction growth time was 2 days or 0.1 mM IPTG was
used.
Figure 3.9: SDS-PAGE of SaHisGS-MBP(X) cell lysate from small scale expression tests
of (A) temperature and post-induction growth time at 37 ◦C and (B) IPTG concentration
at 20 ◦C . Molecular weight ladders are present in unmarked lanes with size label below
corresponding protein band. Odd lane numbers are soluble fractions and even lane
numbers are insoluble fractions. Lanes 1–2 and 5–6 were control samples and lanes
3–4 and 7–8 were test samples. In (A), lanes 1–4 had post induction growth times of 20
hours and lanes 5–8 had 44 hours. In (B) lanes 1–4 used 0.5 mM IPTG and lanes 5–8
used 0.1 mM IPTG. Lane (L), sample type (s), control sample (C), test sample (S), IPTG
concentration (I), post-induction growth time (G).
E. coli Strains
No over-expression (soluble or insoluble) of SaHisGS-MBP(X) was found using C43(DE3)
or SoluBL21 cells (Figure 3.10), despite varying temperature and post-induction growth
time (not shown). Over-expression of SaHisGS-MBP(X) did occur in Origami 2 cells
at 37◦C but the target protein was in the insoluble fraction. This is a good indication
that the plasmid has been successfully modified as all components were present for an
over-expression, however, in this case, inserting MBP into the plasmid has not benefitted
SaHisG solubility.
Given that even if SaHisGS-MBP(X) was to move across to the soluble fraction under
different conditions, there is nothing to ensure that SaHisGS would not crash out after
cleavage with TEVP to remove the 6xHis-tag and MBP from the target. Due to this, no
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further SaHisGS-MBP conditions were tested.
Figure 3.10: SDS-PAGE of SaHisGS-MBP(X) cell lysate from small scale expression tests
of SoluBL1, Origami 2 and C34(DE3) at (A) 37 ◦C and (B) 16 ◦C. Molecular weight
ladders are present in unmarked lanes with size label below corresponding protein
band. Odd lane (L) numbers are soluble fractions and even lane numbers are insoluble
fractions. Lanes A1–2, A7–8, B1–2, B5–6 and B9–10 were control samples and lanes
A3–6, A9–12, B3–4, B7–8 and B11–12 were test samples. Lanes A1–6 and B1–4 used
SoluBL21 cells, A7–12 and B5–8 used Origami2(DE3) cells and B9–12 used C43(DE3)
cells.
Sequencing of SaHisGS-MBP -pJ411
The SaHisGS-MBP-pJ411 (constructs X and M) were sent for commercial sequence
analysis (Eurofins Genomics) to ensure that that modified plasmid contained the full
MBP sequence. The sequencing analysis confirmed a 736 base pair stretch correlating
to the desired SaHisGS-MBP-pJ411 sequence in construct M. Furthermore, this span
confirmed the successful joining of the MBP G-block and the original plasmid SaHisGS
gene.
Unfortunately, with the SaHisGS-MBP(X)-pJ411 plasmid, only a 174 base pair stretch
was confirmed and did not include the G-block and SaHisGS join. Since the X construct
was used for all of the expression tests it is possible that they are not a true representation
of SaHisGS-MBP-pJ411. However, over-expression was observed in Origami 2 cells which
does indicate that the plasmid is fully inducible. Repeat expression tests using Construct
M could probe the Construct X results but this was deemed unlikely to provide fruitful
results.
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3.1.5 Large Scale SaHisGS-pJ411 Protein Purification Solubility Trials
It was hoped that SaHisGS (if present at levels lower than that visible by SDS-PAGE from
1 ml of culture) would concentrate on the column and become visible when eluted under
the gradient conditions of the column. However, this was not the case for SaHisGS-pJ411
in C43(DE3), both of which were unsuccessful under the conditions tested. Potential
bands, at a similar height on the gel to where SaHisGS was expected (∼24kDa,) were sent
for mass spectrometry identification but were subsequently identified as general E. coli
proteins (not shown).
3.1.6 SaHisGS-pJ411 Tris/Bis Tris Lysis Buffer Solubility Trials
Alternative lysis buffers were tested to determine whether poor solubility was due to
SaHisGS instability in Bug Buster or Buffer A1. Bis-Tris and Tris buffers were trialled
with different additives including amino acids, reducing agents and detergents. A
selection of the results are shown in Figure 3.11.
Figure 3.11: SDS-PAGE gel from (A) Tris and (B) Bis-Tris buffer screen for soluble
SaHisGS . Molecular weight ladders are present in unmarked lanes with size label below
corresponding protein band. Odd lane (L) numbers are soluble fractions and even lane
numbers are insoluble fractions. Lanes 1–2, 5–6, 9–10, 13–14 were control samples and
lanes 3–4, 7–8, 11—12 and 15 were test samples. Lanes 1–4 contained Igepal CA360, 5–8
contained Triton X100, 9–12 contained β-mercaptoethanol and lanes 13–15 contained
SaHisZ. Red boxes indicate soluble SaHisGS bands. Note that some wells ran poorly and
were repeated (not shown).
Overall the alternative buffers performed less well than Bug Buster at protein extraction
(Figure 3.1), but this is to be expected since Bug Buster is specifically formulated for
this purpose. From the Tris buffers screened only the buffer containing purified SaHisZ
showed a band by SDS-PAGE that may be attributed to soluble SaHisGS (Figure 3.11
A, red square). It was hoped that SaHisZ would pull SaHisGS into the soluble fraction
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by forming holoenzyme complex. Well overflow contamination from the neighbouring
insoluble sample was ruled out by repeating with a blank lane between each sample (not
shown). A band at ∼24 kDa was still present in the soluble fraction. This was confirmed
to be SaHisGS by MALDI mass spectrometry. Since in vivo SaHisGS and SaHisZ associate
with each other to form the ATPPRT complex it is likely that upon cell lysis the SaHisZ
in the buffer helps to stabilise soluble SaHisGS . This effect is also seen when SaHisZ is
added to a Bis Tris buffer. See Section 3.1.8 for further SaHisZ conditions tested.
Of the Bis Tris buffers tested, two more potential lysis buffers leading to soluble SaHisGS
were noted (Figure 3.11 B). The addition of Triton X100 led to a protein band at ∼24
kDa that was not present in the pre-induction control samples. Detergent is commonly
used to aid protein solubility however they are not compatible with many analytical
techniques, including mass spectrometry. Due to this, a buffer containing detergent is not
desired. However, the addition of the reducing agent β-mercaptoethanol (BMCE) to Bis-
Tris also resulted in a protein band at ∼24kDa that was not present in the pre-induction
controls (Figure 3.11 B, red square). This was repeated to confirm no cross contamination
had occurred (not shown). It is likely that reducing agents such as BMCE are capable
of stabilising SaHisGS by reducing disulphide bonds that may form within the protein.
Unfortunately, Bis-Tris is not compatible with the HisTrap FF column used for large scale
purification and Tris (which is compatible) did not produce soluble SaHisGS .
3.1.7 SaHisGS-pJ411 Reducing Agent Buffer Solubility Trials
Reducing agents BMCE and DTT were tested with buffers compatible with a HisTrapFF
nickel column. Overall buffers containing DTT produced a larger amount of soluble
SaHisGS than BMCE (Figure 3.12). DTT is a more desirable reagent since it is a solid
at room temperature and less volatile but when added to Buffer A1 (50 mM HEPES,
500 mM NaCl, 10 mM Imidazole, pH 8) no soluble SaHisGS was obtained. The protein
could be salting out due to the high salt concentration or SaHisGS may be unstable in
imidazole. This was investigated using small scale expression tests to rule out each of
the buffer components (not shown). Only the buffer containing 50 mM HEPES and 4
mM DTT resulted in soluble SaHisGS which was confirmed by ESI mass spectrometry.
A large-scale purification using only HEPES, DTT and imidazole (no salt) in the buffer
was tested but SaHisGS was not collected from any of the column fraction elutions, nor
was it present by eye in the pre-column sample on the resulting SDS-PAGE gel (not
shown). It appears that lack of soluble SaHisGS could be due to both salting out and
imidazole instability. Histidine was tested as an imidazole replacement but with no
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positive result (not shown).
3.1.8 SaHisGS-pJ411 Lysis Buffer Trial with SaHisZ in Buffer
Tris and Buffer A1 components were tested with DTT in the presence of SaHisZ in order
to determine whether SaHisZ could stabilise soluble SaHisGS by forming the holoenzyme
when imidazole was present in the buffer (Figure 3.13). However, it did not appear that
SaHisZ could dramatically alter the soluble stability of SaHisGS in any buffers containing
imidazole, regardless of DTTs presence.
3.1.9 Large Scale SaHisGS Protein Purification Trials with DTT in Buffer
Being unable to use imidazole or histidine in the buffer for protein purification is not
ideal but can be worked around. For example, imidazole could be removed from Buffer
A but still be present in elution Buffer B. This would result in more unspecific proteins
binding to the column initially but would leave SaHisGS in a compatible buffer for the
entirety of the preparation and binding to the column. Alternatively, pH could be used to
elute SaHisGS from the column. The first of these conditions was tested using large scale
protein purification, however SaHisGS was not visible in any of the elution fractions.
Additionally, there was no obvious band present in the pre-column sample that was
subsequently missing in the flow though to suggest SaHisGS had been loaded and bound.
To investigate the whether SaHisGS had been loaded onto the column at all, a 20–25 kDa
section of SDS-PAGE gel of pre-column sample was analysed by mass spectrometry. The
gel band was found to contain no SaHisGS . The only difference between the expression
test where soluble SaHisGS was present and the purification procedure (where it was
not) was the scale up sample preparation. The expression test uses agitation in the lysis
buffer to break open the cells to release SaHisGS whereas the protein purification method
utilises a cell emulsifier. The emulsifier should be more efficient and break up inclusion
bodies but, in this case, it appears it could be be de-stabilising the soluble protein. It
is possible that the protein is denatured due to the high pressure forced upon it in the
emulsifier chamber.
3.1.10 Co-purification of SaHisGS with SaHisZ
A large-scale co-purification of SaHisGS with SaHisZ was trialled to determine whether
formation of the holoenzyme from the beginning of cell paste processing could stabilise
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SaHisGS enough to withstand lysis by emulsifier and remain soluble. By using a large
scale purification it was hoped that enough SaHisGS would be concentrated on the
column for a clear band to be present on the SDS-PAGE gel after elution. Conditions
using 150 mM NaCl or 100 mM KCl were tested. Both purified SaHisZ well, but neither
gave measurable amounts of SaHisGS . Unfortunately it does not seem that SaHisZ was
able to stabilise SaHisGS enough to withstand emulsification.
Emulsification is a relatively harsh cell lysis technique, particularly when compared
to the small expression tests which used agitation with lysis buffer to lyse the cells.
Unfortunately, it would be highly inefficient to attempt cell lysis by agitation for litres of
cells (opposed to 1 ml). Therefore, lysis using a much milder lysis technique, shaking
with glass beads was trialled instead. Unfortunately, no SaHisGSwas present in the
resulting elutions. Gel bands corresponding to 23-25 kDa from each elution step (flow
through and gradient) were tested by mass spectrometry for traces of SaHisGS but no
related protein was found.
3.1.11 Concluding Remarks Pertaining to the Purification of SaATPPRT
Despite extensive attempts to solubilise SaHisGS separately from SaHisZ, none have
been successful. Purifying both subunits separately was desirable for precise calculation
of ATPPRT complex concentration (Equation 2.4) during kinetic studies, for ease of
radioactive labelling in later experiments and for alternative projects planned within the
group. Since separate purification was not successful, preparation to co-express SaHisGS
and SaHisZ together using a pETduet vector (Novagen) had begun. It was hoped that
by expressing both together, the PaATPPRT complex would form and SaHisGS would
be stabilised in soluble form. However, concurrently, Ghssein et al. [133] published
the Biosynthesis of a Broad-spectrum Nicotianamine-like Metallophore in Staphylococcus
aureus. Here, the authors presented identification of a new transport system, previously
unidentified in S. aureus, containing a full ABC transporter suite capable of importing
amino acids, including histidine, into the cell. Consequently, if the cell was deficient
in histidine, for example from a corrupted histidine pathway, S. aureus would be able
to scavenge histidine from the host. It is unknown whether S. aureus would be able
to scavenge enough histidine from the host alone to overcome a compromised histidine
biosynthesis pathway but, given there are currently no in vivo knock out studies proving
otherwise, the enzymes in the S.aureus histidine pathway may not be as suitable a drug
target as originally thought. This, coupled with extensive solubility problems, led to the
cessation of the SaATPPRT project.
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Figure 3.12: SDS-PAGE gel of reducing agent lysis buffer screen for soluble SaHisGS .
Molecular weight ladders are present in unmarked lanes with size label below
corresponding protein band. Sample type (s) are annotated as control samples (C) and
test samples (S). Lanes (L) 1-8 were soluble samples and lanes 10-17 were insoluble
samples. The lysis buffer used in Lanes 1-2 and 10-11 were HEPES and BMCE, lanes
3-4 and 12-13 were Buffer A1 and BMCE, lanes 5-6 and 14-15 were Buffer A1 and DTT,
and lanes 7-8 and 16-17 were Buffer A1 alone. Lane 9 was intentionally left empty.
Figure 3.13: SDS-PAGE gel of a histidine and imidazole buffer screen for soluble
SaHisGS . Molecular weight ladders are present in unmarked lanes with size label
below corresponding protein band. Odd numbered lanes were control samples and even
numbered lanes were test samples. The lysis buffer used in Lanes 1-2 were Tris, NaCl
and SaHisZ, lanes 3–4 were Tris, NaCl, SaHisZ and imidazole, lanes 5–6 were HEPES,
NaCl and SaHisZ, lanes 7–8 were HEPES, NaCl, SaHisZ and imidazole, lanes 9–10 were
HEPES, NaCl, SaHisZ and DTT, lanes 11–12 were HEPES, NaCl, SaHisZ and histidine.
(A) shows soluble fractions and (B) shows insoluble fractions.
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3.2 Expression and Purification of PaATPPRT
3.2.1 Purification of PaHisGS and PaHisZ
Purification of PaHisGS (25213 Da) and PaHisZ (43085 Da) were both carried out as
previously described [20] utilising two nickel column purification steps, one before and
after TEVP cleavage of the 6xHis-tag (Figure 3.14). Initially, purification was as expected
with purity >95% (Figure 3.15) and yields in the region of 30–40 mg L−1for both PaHisGS
and PaHisZ.
Figure 3.14: FPLC elution profile of PaHisZ second nickel column purification step after
TEVP cleavage from A) PaHisG and B) PaHisZ.
3.2.2 Method Development of Larger Scale PaHisZ Purification
A larger scale purification was trialled, utilising a 20 ml nickel HisTrap column and 5 L of
cells compared to the standard 5 ml column and 2 L of cells. It was hoped that a greater
amount of protein could be obtained in a similar time period since a large quantity of
protein is required for ‘pre-steady state’ kinetics. Unfortunately, using the larger column
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did not improve purification attempts. PaHisZ with >95% purity was obtained but with
a yield of 90 mg total (18 mg L−1) where as the standard purification protocol (using a
column 5x smaller), obtains a greater amount of protein per litre of cells (30-40 mg L−1)
in substantially less time. The purification suffered from protein crashing out multiple
times, a third chromatographic step and an extra 4 weeks purification time. Method
development for a larger scale process was abandoned at this point in favour of smaller
batch purification.
Figure 3.15: SDS-PAGE of final purity (A) PaHisGS and (B) PaHisZ purification. The
first lane in both gels correspond to molecular weight marker, size as annotated directly
underneath. Lanes labelled 1 and 2 are duplicates.
3.2.3 Troubleshooting PaATPPRT Purification Issues
Unfortunately, for a sustained period of time, purification was resulting in enzymes with
considerably reduced activity (∼4-fold drop). Initially it was thought that the pH of
the assay buffer may have deviated from the required, pH 8.5. Figure 3.16 shows an
example of the change in rate based on pH of the assay buffer. Figure 3.16 also shows the
differences in rate observed for an original, fully active batch of PaHisGS (blue) compared
to one of the poor batches (orange). One of the differences between the good and poor
quality batches was concentration. Although previously, batches of protein had been
concentrated successfully to > 500 µM, the large difference in concentration between
working batch 1 (19 µM) and compromised batch 2 (420 µM) led to troubleshooting of the
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concentration process. Additionally, the concentrating process became under scrutiny
due to observation that the poor batch accumulated many ‘microbubbles’ upon the
surface when concentrating (a characteristic of denatured protein). New ultrafiltration
membranes were used with the ultrafiltration concentrator, but this did not improve
activity, nor did switching to using a centrifugal concentrator, or leaving batches very
dilute.
Figure 3.16: pH dependence on the rate of PaHisGS activity corrected for total enzyme
used. Batch 1 is one of the original, fully active batches (blue) and Batch 2 is one of the
poor rate batches of PaHisGS (orange).
Differential Scanning Fluorimetry (DSF), a technique where a fluorescent marker binds
to exposed hydrophobic regions of protein, was carried out for a batch of poor
quality PaHisGS to determine whether the inactivity was due to a stability defect.
As the temperature increases during the procedure, the protein will unfold exposing
hydrophobic regions. Figure 3.17 shows that compared to the original thermal
denaturation of active PaHisGS (Tm = 60.0 ◦C ± 0.1 alone, and Tm = 66.0 ◦C ± 0.1 with
PRPP) [102], the thermal denaturation of compromised protein is considerably different
with the poor batch containing a step in the thermal denaturation. This suggests that the
protein may be present in two states: one folded correctly and the other not. This could
account for the partial activity seen given that it is unlikely misfolded protein would
be active. Determining the factor responsible for this mis-folding was not immediately
forthcoming, particularly since other, completely unrelated projects were experiencing
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Figure 3.17: Differential scanning fluorimetry-based thermal shift assay of PRPP binding
to PaHisGS . Thermal denaturation of two batches of PaHisGS . The compromised batch
is shown in orange (no ligand) and brown (PRPP ligand) and the standard batch is shown
in light blue (no ligand) and brown (PRPP ligand).
similar protein purification issues.
New glycerol stocks were prepared from fresh overnight cultures but upon retesting
this made no improvement to activity. All stock solutions and buffers were prepared
fresh for the entirety of the procedure (including all buffers that the protein would
come into contact with indirectly, for example the buffers used to strip and recharge the
nickel columns) but no improvement in activity was seen. Brand new plasticware was
sourced where possible or cleaned thoroughly and rinsed extensively, where not. In the
event that the dialysis tubing contained detrimental contaminants, all dialysis bags were
rinsed in 1 mM ethylenediaminetetraacetic acid (EDTA) before use.
Although a different HisTrap FF column was tried with no success near the beginning of
troubleshooting, the alternative column had been previously used and re-charged many
times in the past. It was thought that perhaps nickel was leaching out from the older
column and so 1 mM EDTA was used to rinse the column and added to the purification
buffers to chelate any free ions. A small improvement in PaHisGsactivity was observed
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but activity was still significant reduced. This indicated that the column may indeed be
compromised. A brand new HisTrap FF column was tested and PaHisGs activity was
restored.
Unfortunately, despite PaHisGs activity reverting back to full activity when un-
complexed and un-activated, upon complexing with PaHisZ, activity was lost again.
Subsequently, a second factor affecting PaHisZ regulation was at play and not yet
accounted for. Similar factors were checked and retested as before. The main difference
in purification between the two subunits is an additional volume of TEVP used, and a
longer cleaving time for PaHisZ than for PaHisGS . Many variables relating to TEVP were
trialled, including purifying TEVP in fresh buffer. A batch of PaHisZ without TEVP
cleavage was prepared and found to have full activity. This narrowed down the potential
variables causing compromised activity to a factor directly relating to TEVP.
This factor was finally determined to be the glycerol in the TEVP buffer. Correspondence
with other lab groups in the building confirmed experiencing issues with glycerol,
mainly over-pressuring of gel filtration columns and proteins failing to crystallise since a
change of glycerol supplier from Sigma Aldrich to Scientific Laboratory Supplies. Upon
purifying both TEVP and PaHisZ with glycerol from Sigma Aldrich (and a glycerol free
purification using phosphate buffer instead), activity was fully restored to the complex.
3.2.4 Purification of 6HPaHisGS and 6HPaHisZ
The 6HPaHisGS (26831 Da) and 6HPaHisZ (44703 Da) purified easily with no
unexpected issues. Both proteins were obtained with purity >95% with yields in the
region of 30 mg L−1 and 25 mg L−1 for PaHisGS and PaHisZ respectively. This is slightly
higher than the yield of protein gained after TEVP cleavage but this is to be expected
since cleavage with TEVP is not 100% efficient and some uncleaved protein is left bound
to the second nickel column.
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3.3 Kinetic Studies of PaATPPRT
Before inhibition kinetics of PaATPPRT were carried out, preliminary experiments
regarding general kinetic characteristics were determined and confirmed to match
previously published data for PaATPPRT, where applicable. Unless otherwise stated,
data points are the mean of duplicates ± fitting error.
3.3.1 Determination of KD
PaHisZ (0–18 µM) was titrated into 0.67 µM PaHisGS resulting in a hyperbolic
relationship that was fitted to Equation 2.4 to determine the dissociation constant, KD
= 0.8 ± 0.3 µM (Figure 3.18 A). This matches the previously published KD for PaATPPRT
[20]. This KD was used in the Morrison equation (Equation 2.4) to determine all
concentrations of PaATPPRT.
Figure 3.18: Titration of PaHisZ into (A) PaHisGS and (B) 6HPaHisGS to determine KD .
The line is the best fit to Equation 2.4 and data points are the mean of duplicates ± fitting
error.
3.3.2 Determination of KM Values
To confirm the KM values for each substrate from the current study matched those
previously published [20] the rate of PRATP formation was followed while one substrate
was held constant and the other substrate concentration was varied. For PRPP the
KMPRP P = 0.24 ± 0.07 mM (Figure 3.19 A). This was 2.5-fold lower than previously
found for PaATPPRT (KMPRP P = 0.6 ± 0.1 mM [20]) but within error for different
batches. This puts the current KMPRP P found 5-, 16-, 21- and 13-fold higher in
comparison to the KMPRP P determined at similar temperatures for mesophilic ATPPRT’s
from Mycobacterium tuberculosis, Campylobacter jejuni, Salmonella typhimurium, and
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Lactococcus lactis, respectively [58, 72, 86, 134]. Similarly for ATP, the KMAT P = 0.68 ±
0.09 mM (Figure 3.19 B) and was 2.6-fold lower compared to that published previously
for PaATPPRT (KMAT P = 1.8 ± 0.2 mM) [20]. This places the current KMAT P 2.6-, 7- and
6-fold higher than previously published for mesophilic ATPPRT’s from M. tuberculosis,
C. jejuni and S. typhimurium, and 4-fold lower for L. lactis, respectively[58, 72, 86, 134].
Figure 3.19: [KM substrate saturating curves against (A) PRPP (the line is the best fit to
Equation 2.5) and (B) ATP (the line is the best fit to Equation 2.6) for PaATPPRT. Data
points are the mean of duplicates ± fitting error.
Surprisingly however, the current study observed substrate inhibition with a Ki = 17
± 5 mM at ATP concentrations above 2.8 mM. Equation 2.6, which contains a term for
substrate inhibition, was used to obtain the fit. This has not previously been observed in
any short-form ATPPRT, including P. arcticus, except for ATP:Mg2+ complex inhibition in
S. typhimurium (Ki = 0.8 mM) if [Mg2+] was greater than 5 mM. The presence of substrate
inhibition denotes that in high concentration of substrate the activity is reduced. This
most-commonly observed deviation from Michaelis Menten kinetics is often an artefact
of using abnormally high substrate concentrations in vitro [135]. Given that the Ki value
is far above working concentrations, this is most likely the case here. However, substrate
inhibition can, at times, prove to be of biological advantage. For example, substrate
inhibition of tyrosine hydroxylase allows for a steady synthesis of the product, dopamine,
regardless of fluctuations in tyrosine (substrate) concentration due to the digestion of
meals [117]. Often substrate inhibition is competitive (caused by two substrate molecules
binding in one binding site [136]) and this is the most likely process happening in
PaATPPRT. Although the possibility of a weak allosteric regulatory substrate binding
site cannot be ruled out empirically, there has been no evidence for this in previously
published crystal structures with ATP bound to PaATPPRT [101].
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3.3.3 Leaving the 6xHis-tag uncleaved does not alter the characteristics of
PaATPPRT.
Amongst the enzymology community there is debate over whether it is essential for a
histidine tag to be removed before kinetic or structural endeavours. There are many
examples where leaving the 6xHis-tag on has not caused any adverse effect [59, 137, 138]
but also instances where removing the 6xHis-tag has caused change [88, 139, 140]. In
the present PaATPPRT study the 6xHis-tag was removed from almost all investigations
so that the protein was monitored in the form closest to the one which would be present
in vivo, while also to avoid the risk of the tag inadvertently interfering with structure
or protein-protein interactions. However, a comparison of KD , KM and IC50 values were
carried out between tagged and untagged protein to evaluate whether keeping the 6xHis-
tags attached to the N-terminus of the protein causes any substantial differences.
Comparison of the KD and KM for PaATPPRT and 6HPaATPPRT
6HPaHisZ (0–18 µM) was titrated into 0.17 µM 6HPaHisGS which resulted in KD = 1.1 ±
0.2 µM (Figure 3.18 B). This is within a similar region of the KD of untagged PaATPPRT
(KD = 0.8 ± 0.3 µM) (Figure 3.18 A) and so it can be considered that the 6xHis-tag does
not change the affinity of PaHisGS for PaHisZ.
Figure 3.20: [KM substrate saturation curves against PRPP (A) and ATP (B) for
6HPaATPPRT. In (A) the line is the best fit to Equation 2.5 and (B) to Equation 2.6 (red)
and Equation 2.7 (black). Inset shows residuals of the fit to Equation 2.7. Data points are
the mean of duplicates ± fitting error.
For the 6HPaATPPRT, KMPRP P = 0.07 ± 0.008 mM (Figure 3.20 A). This was 14-fold lower
than found for untagged PaATPPRT (KMPRP P = 0.24 ± 0.07 mM) in this study. This is
larger than would be expected from within error only, between different batches. On
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the other hand, KMAT P = 0.5 ± 0.1 mM with Ki = 10 ± 3 mM was comparable (Figure
3.20 B) to untagged PaATPPRT in this study (KMAT P = 0.68 ± 0.09 mM with Ki = 17 ± 5
mM). This implies that substrate affinity for the enzyme is unchanged when the 6xHis-
tag remains bound to the protein for ATP but substrate affinity for the enzyme increases
for PRPP under these circumstances. However, the crystal structure of PaATPPRT:PRPP
[101] shows the N-terminus 6xHis-tag is not in close proximity to the PRPP binding site.
Perhaps this is an artefact of the purification process, since purification without TEVP
cleavage is considerably shorter and hence the cold-adapted enzyme spends less time at
4 ◦C. A crystal structure of PRPP bound to 6HPaATPPRT could help elucidate if this is
the case or a structural ramification does indeed occur when the 6xHis-tag remains on
the protein.
Figure 3.21: Simplified scheme of Haldane substrate inhibition for a one substrate
reaction where a second substrate molecule may bind to the enzyme, forming complex
SES, and resulting in inhibition.
It should also be noted that in this instance, although substrate inhibition was observed
as in the cleaved protein, using the same equation to model this inhibition (Equation 2.6)
did not give a convincing fit (R2 = 0.95, Figure 3.20 red line). A much more appealing
fit (R2 = 0.99 Figure 3.20 black line) was obtained using equation 2.7 instead [117].
This equation differs from the standard substrate inhibition Equation (2.6) by including
[substrate] to the power of 2. This means that as the rate tends to zero (complete
inhibition), [S] becomes larger since increasingly more enzyme is unavailable due to
formation of a dead-end ternary complex with two bound molecules of substrate [117].
A simplified scheme of such a reaction is shown in Figure 3.21. It is worth noting that
using this equation (proposed by Haldane [141]) to describe the cleaved protein gave the
same KM and Ki as the standard substrate inhibition equation.
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3.3.4 AMP is an inhibitor of PaATPPRT and PaHisGS
AMP is an inhibitor of PaATPPRT with IC50 = 333 ± 29 µM (Figure 3.22 B) and h = 0.88
± 0.08. IC50 is the concentration of inhibitor (in this case AMP) required to give half the
maximal activity of PaATPPRT and h is the Hill number which incorporates a term for
cooperativity into Equation 2.8. If the Hill number is above 2 for complexes with four
binding sites (PaATPPRT), then there is significant positive cooperativity at play. Below
this value, the Hill number is of less importance, but incorporation of the term often
reduces the R2 of the fit and gives a better model [142].
Figure 3.22: Dose-response curve for AMP with (A) PaHisGS and (B) PaATPPRT. Lines
are the best t to Equation 2.8. Data points are the mean of duplicates ± fitting error.
The relatively high IC50 value in the mid-micromolar range makes ATP a much weaker
inhibitor of PaATPPRT than histidine (Section 3.4.2).PaHisGS is 4x more sensitive to
AMP than PaATPPRT with IC50 = 81 ± 6 µM and a h = 1.13 ± 0.09 (Figure 3.22 A). This
suggests that the hetero-octamer desensitises the complex to inhibition by AMP. Since
the AMP:ATP ratio depends on the energy status of the cell, this inhibition links the
histidine pathway with the cell’s metabolic status [143]. Given that the AMP inhibition
is weaker for PaATPPRT than PaHisGS , it follows that the cell relinquishes more control
to feedback inhibition by histidine for the octameric complex but is more reliant on AMP
inhibition to control PaHisGS activity alone. This is logical, given PaHisGS ’s insensitivity
to feedback inhibition and the requirement to conserve resources in times of low energy
availability in the cell. However, there is currently no data to determine how much free
PaHisGS is available in the cell and therefore how much importance this inhibition has
in vivo. AMP inhibition of ATPPRTs has been reported in HisGLs (M. tuberculosis, E. coli
and C. jejuni [86, 104, 144]) and in HisGS (L. lactis [91]). The AMP inhibition of PaHisGS
in this study was published as part of [102], a R.G da Silva group paper with kinetic data
on PaHisGS activation and engineering by Ms Gemma Fisher.
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Figure 3.23: Double-reciprocals of substrate saturation curves against ATP (A and C)
and PRPP (B and D) in the presence of AMP for PaATPPRT (A and B) and PaHisGS (C
and D). Data points are the mean of duplicates ± fitting error from individually fitted
double-reciprocal plots, and lines are linear regressions of the data. Residuals from the
fit of A-D to Equation 2.9. AMP inhibition against ATP (E and G) and PRPP (F and H)
for PaATPPRT (E and F) and PaHisGS (G and H).
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AMP is a competitive inhibitor against both substrates for PaATPPRT and PaHisGS
(Figure 3.23), as visualised by the characteristic convergence of lines (corresponding
to varying concentrations of inhibitor) on the y-axis of a double reciprocal plot. If the
inhibition type had been uncompetitive, the lines on a double reciprocal plot would be
parallel and for non-competitive inhibition the lines would converge to the left of the
y-axis. Determined by global fitting to Equation 2.9, ATP inhibition the Ki = 25 ± 3 µM
against ATP and Ki = 46 ± 2 µM against PRPP for PaATPPRT and Ki = 52 ± 8 µM against
ATP and Ki = 25 ± 5 µM against PRPP for PaHisGS . The values for PaATPPRT are around
7-fold and 10-fold lower than those of previous characterised HisGL ATPPRTs [86, 109]
and over 27-fold lower than that published for short-from ATPPRT, L. lactis [72]. This
implies that PaHisGS activity is more rigorously regulated by AMP than mesophillic
ATPPRTs.
Initially it may be surprising that AMP is competitive versus both substrates, which
by definition implies that AMP competes for the binding site of both PRPP and ATP.
However, this study confirms the findings of the PaHisGS-AMP crystal structure which
shows this is exactly the case (Figure 3.24). AMP sits across both the ATP and PRPP
binding regions in the active site of PaHisGS . The 5’-PO42− group of AMP makes similar
interactions with the protein as the corresponding group in PRPP, and the adenine of
AMP sits in the same site as the adenine of ATP. This is the same binding mode as found
in other ATPPRTs [86, 104, 144].
Figure 3.24: Crystal structure of (A) PaHisGS-PRPP-ATP and (B) PaHisGS-AMP binding
site. The figure presents magnesium atoms (green spheres) nitrogen atoms (blue), oxygen
atoms (red), phosphorus atoms (orange), ligands (stick models, carbon in cyan), protein
backbone (ribbon diagram with selected main and side chain residues as stick models,
carbon in grey) [101].
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3.3.5 TIH is a Histidine Analogue that does not Inhibit or Activate
PaATPPRT
TIH (3-(2-thienyl)-L-alanine) is an analogue of histidine which has a thiophene ring in
place of histidine’s imidazole ring and is a known allosteric activator of M. tuberculosis
ATPPRT [92]. TIH had no effect on catalysis with PaATPPRT: no change in rate occurred
when TIH was present in the assay (Figure 3.25). It is not surprising that HisGL and
HisGS are activated/inhibited by different molecules since the regulatory domain of
long form ATPPRTs descended from very different ancestor proteins than the regulatory
subunit found in short-form ATPPRTs. However, the fact that histidine (which contains
an imidazole ring that is capable of making polar contacts) is an allosteric inhibitor
and TIH (with a thiophene ring which cannot make polar contacts) is not, suggests that
interaction with the imidazole ring are essential for allosteric inhibition of PaATPPRT.
Figure 3.25: Effect of TIH on PaATPPRT rate of PRATP formation.
3.3.6 Other Effectors of PaHisGS
Substrate-like molecules (Figure 3.26) were tested for changes to the rate of product
formation by PaHisGS . Ribose-5-phosphate (R5P) is a PRPP analogue lacking the
phosphate but it had no effect on PaHisGS activity (Figure 3.27 A). This is surprising
due to R5P’s similarity to the substrate. Given that the phosphate interactions
with magnesium are no longer accessible, perhaps there is not sufficient structural
contacts with the protein to hold R5P in the binding site long enough for sampling of
conformations leading to dead-end complexes or structural changes to be observed.
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Figure 3.26: Structures of (1) AMP - adenosine monophosphate, (2) ADP -adenosine
diphosphate, (3) ATP - adenosine triphosphate, (4) dATP - 2’-deoxyadenosine
triphosphate, (5) CTP – cytosine triphosphate and (6) ITP – inosine triphosphate.
Given their similarity to ATP, other molecules dATP, CTP and ITP (Figure 3.26) were
tested for inhibitory effects on PaHisGS (Figure 3.27B). In addition, dATP was assessed
as an alternative substrate for PaHisGS .
CTP and dATP are not inhibitors of PaHisGS and dATP is not an alternative substrate
as the rate was below the limit of the detector (absorbance = 0.009 and 0.0015 for
both repeats). In the case of CTP it appears that the 5 membered ring-triphosphate
moiety alone is not capable of stabilising the molecules in the ATP binding site to form
a dead-end complex or reaction. This suggest that the contacts between the adenine
ring and the enzyme are important for substrate stabilisation within the active site and
triggering of the ATPPRT reaction. On the other hand, the only difference between
ATP and dATP is two hydroxyl groups on the adenosine in ATP compared to only one
in dATP. This implies that the hydroxyl at the 2’ position on the adenosine of ATP is
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that which is essential for stabilisation of the substrate within the active site (since
when it is missing in dATP no reaction or inhibition occurs). This is an interesting find
which is substantiated by the PaHisGS :PRPP:ATP structure [101] which shows Asp94
hydrogen bonds to the 2’OH (and 3’OH) of ATP. This is also true of C. jejuni [86] and
M. tuberculosis [104] and so it would be interesting to determine whether mutating this
residue to an amino acid incapable of interacting with the 2’OH hydroxyl would alter
activity in PaHisG and PaATPPRT. Since the Asp94 is a conserved residue across all 17
short-form ATPPRTs aligned in Alphey et. al [101], it is highly likely that removing this
interaction would be significantly detrimental to activity.
Figure 3.27: Effect of CTP (A) and ITP (B) on activity of PaHisGS . (B) shows a dose-
response curve for ITP concentration fitted to Equation 2.8 and inset shows the residuals
of the fit. Data points are the mean of duplicates ± fitting error and the inset is the
residual error from the fit.
It appears that ITP is a weak inhibitor of PaHisGS with IC50 = 2400 +/- 700 µM (Figure
3.27) although the fit is not ideal (R2 = 0.86, Figure 3.27 (B) inset) which may be related
to the quality of the protein that was used for this study (see Section 3.2.3) or ITP
complexing with Mg2+. It could be likely that the inosine ring is able to interact with
the protein enough to stabilise ITP in the ATP binding site more so than CTP. Given the
minimum inhibitory effect of ITP, obtaining a crystal structure of ITP bound to PaHisGS
would not be simple and unlikely to be of high value.
3.3.7 ADP is an Alternative Substrate for PaATPPRT
ADP was reported as an alternate substrate for PaHisGS [102] but interestingly, ADP
has been reported as an inhibitor of HisGLs ATPPRTs [72]. The crystal structure of
PaHisGS-PRPP-ADP was similar to the PaATPPRT:PRPP:ADP structure [101] implying
that ADP could also replace ATP as a substrate for PaATPPRT.
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Figure 3.28: Kmsubstrate saturation curves against PRPP (A) and ADP (B) for PaATPPRT
with ADP as substrate. (C) and (D) are comparison data from Figure 3.19 with ATP as
substrate. The line is best fit to Equation 2.5. Data points are the mean of duplicates ±
fitting error.
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ADP as an alternate substrate to ATP was indeed confirmed via steady-state kinetics
(Figure 3.28). The KMPRP P = 0.7 ± 0.1 mM and KMADP = 0.68 ± 0.09 mM with kcat = 2.6
± 0.4 s−1. These values are comparable to that found for ADP as a substrate of PaHisGS
(KMPRP P = 0.91 mM ± 0.08 and KMADP = 3.2 mM ± 0.3) [102]. Notably, no substrate
inhibition was observed for ADP as the substrate.
Figure 3.29: Dose-response curve for histidine with ADP as the substrate for PaATPPRT.
The line is best fit to Equation 2.8. Data points are the mean of duplicates ± fitting error.
Additionally, histidine is still an inhibitor when ADP is used as the substrate. The IC50
= 28 ± 3 µM and h = 1.31 ± 0.09 (Figure 3.29), are effectively the same as when ATP was
used as the substrate (IC50 = 31 ± µM 1). It appears that replacing the substrate with
ADP causes no observable consequences for the formation of PRADP over PRATP by
PaATPPRT or allosteric inhibition by histidine. This implies that the interaction between
Arg73 of PaHisGS and the γ-PO-4 group of ATP is not essential for catalysis or allosteric
inhibition, since this is absent when ADP replaces ATP [102].
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3.4 Kinetic Studies of PaATPPRT Inhibition by Histidine
3.4.1 Differential scanning fluorimetry thermal shift assays of PaHisZ
Differential scanning fluorimetry (DSF) thermal shift assays of PaHisZ in the presence of
histidine were carried out to determine whether a mathematical term corresponding to
histidine binding to free PaHisZ would need to be included in kinetic calculations. This
was determined not to be necessary, although histidine does bind to free PaHisZ (Figure
3.30(A)).
Figure 3.30: Differential scanning fluorimetry-based thermal shift assay of PaHisZ in the
presence of histidine. Thermal denaturation curves of PaHisZ in the presence of 0 – 8
mM histidine (A). Histidine dependence on PaHisZ Tm (Equation 2.1) is shown in (B).
Data are the mean of quadruplicates.
The Tm of PaHisZ denaturation increased upon increasing concentration of histidine.
This corresponds to stabilisation of PaHisZ from binding of histidine. However, the KD
of histidine binding to free PaHisZ is 2.8 ± 0.8 mM (Figure 3.30 (B)). This means that if
there were 2.8 mM of histidine in the assay, half of free PaHisZ sites would be bound.
This value is 9x higher than the maximum concentrations used for IC50 determination
(640 µM) and 35x higher than the maximum concentration used in steady-state kinetics
studies (80 µM). Therefore, any binding of histidine to free PaHisZ would be negligible.
Additionally, this suggests that histidine is capable of binding to PaHisZ in the absence
of PaHisGS but at much lower affinity than when PaATPPRT is in the hetero-octameric
arrangement. The very high KD may also suggest that binding may be unspecific, and
not reflect the binding mode in the hetero-octamer. It is possible that the structure of
the binding site in PaHisZ alone differs to that in the complex, which could result in
a different KD . Unfortunately, it is not practical to carry out a similar study on the
holoenzyme as denaturation of the complex obscures the findings. Comparison of the
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holoenzyme crystal structure to that of PaHisZ crystallised on its own could highlight
the degree of similarity of the binding sites. However, given how much higher the KD is
from working concentrations, differences in the binding sites are unlikely to be so vast as
to affect calculations going forward.
3.4.2 Determination of IC50 for Histidine Inhibition
Histidine was confirmed as an inhibitor of PaATPPRT with an IC50 value of 35.5 ± 0.8 µM
and h = 1.30 ± 0.04 (Figure 3.31 A). The hill number incorporates a term for cooperativity
into Equation 2.8. If the Hill number is above 2 for complexes with four binding sites
(PaATPPRT), then there is significant positive cooperativity at play. Below this value, the
Hill number is of less importance, but incorporation of the term often reduces the R2 of
the fit and gives a better model [142].
This IC50 value is in agreement to both values reported for the inhibition of M.
tuberculosis HisGL ATPPRT [58].
Figure 3.31: Dose-response curves for histidine concentration (A) for PaATPPRT and
(B) 6HPaATPPRT. Lines are the best fit to Equation 2.8 and data points are the mean of
duplicates ± fitting error.
Histidine inhibits 6HPaATPPRT with IC50 = 70 ± 2 µM and h = 1.84 ± 0.09, (Figure 3.31
B) comparable to untagged PaATPPRT (35.5 ± 0.8 µl). Therefore, it does not appear that
removing the histidine tag has any considerable effect on histidine inhibition.
3.4.3 Determination of Kivalues for Histidine Inhibition
For PaATPPRT, histidine is a non-competitive inhibitor versus both substrates, ATP and
PRPP (Figure 3.32 and Figure 3.33), with the characteristic pattern of lines converging
to the left of the y-axis on a double reciprocal plot. The Kis= 22 ± 6 µM and Kii =
38 ± 7 µM against PRPP and Kis = 56 ± 25 µM and Kii = 36 ± 5 µM against ATP, by
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global fitting to Equation 2.10. Kis reports on inhibitor binding to the free enzyme,
while Kii , to the enzyme-substrate complex. Given that the Kii and Kis values are
similar, histidine can be considered to have almost equal affinity for the relevant enzyme
forms, free PaATPPRT, PaATPPRT:PRPP, and PaATPPRT:PRPP:ATP. Histidine is also a
non-competitive inhibitor of both HisGL and HisGS ATPPRTs [68, 72, 84, 86]. Of the
HisGL ATPPRTs characterised, only the M. tuberculosis enzyme differs with inhibition
uncompetitive against ATP, although the Ki ’s were still comparable [58]. Ki ’s were also
comparable for ATPPRTs from C. jejuni [86], and L. lactis [72] but almost 10x lower than
the Ki ’s stated for S. typhimurium [134] and Thermotoga maritima [84] ATPPRTs.
Figure 3.32: PaATPPRT inhibition by histidine. Double-reciprocals of substrate
saturation curves in the presence of histidine against PRPP (A) and ATP (B) by global
fitting to Equation 2.10. Residuals of the model fitting are shown for PRPP (C) and
ATP (D). Data points are the mean of duplicates ± fitting error from individually fitted
double-reciprocal plots, and lines are linear regressions of the data.
Replots of histidine inhibition data. Slope and intercept replots of the individually
fitted double-reciprocal data for PaATPPRT inhibition by histidine against PRPP and
ATP. Data points are value ± fitting error from individually fitted double-reciprocal plots,
and lines are linear regressions of the data.
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Figure 3.33: Replots of histidine inhibition data. Slope and intercept replots of the
individually fitted double-reciprocal data for PaATPPRT inhibition by histidine against
PRPP and ATP. Data points are value ± fitting error from individually fitted double-
reciprocal plots and lines are linear regressions of the data.
3.4.4 Effect of Histidine on the Approach to Steady State.
Approach to steady state, or ‘pre-steady state’ kinetics refers to the period before the
steady state is reached. Studying the formation and consumption of products and
reactants during this period can inform on binding order and the rate limiting step
of the reaction. PaATPPRT follows an ordered mechanism with PRPP binding to the
enzyme first [102]. This is the opposite order to other ATPPRTs characterised [69, 75]
but product release follows the same pattern as both long and short-form ATPPRTs
previously published with PPi leaving first, followed by PRATP (Figure 3.34).
The rate limiting step for PaATPPRT catalysis is product release (as determined by the
presence of an initially large rate or ‘burst’ in previous pre-steady kinetic experiments)
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[102]. This contrasts with PaHisGS alone, where the rate-limiting step is likely chemistry.
It can therefore be said that the rate limiting step of PaATPPRT is determined by the
activation, or not, of PaHisGS . The effect of histidine on the approach to steady state is
hence of interest.
Figure 3.34: Kinetic mechanism of PaATPPRT is sequential and ordered with ATP
binding after PRPP and PRATP leaving after PPi. Histidine can bind to all three forms
of the enzymes depicted by an asterisk.
When histidine in not present in the assay and ATP is rapidly mixed with PaATPPRT
pre-incubated with PRPP, an initially large rate or ‘burst’ is observed before the steady-
state (Figure 3.35, red line). The amplitude of this burst phase is 3.11 ± 0.01 µM with an
uninhibited steady state rate of 16.36 ± 0.01 µM s−1. This burst amplitude remains the
same, within experimental error, at 3.49 ± 0.01 µM when histidine is present at 640 µM
and pre-incubated with ATP upon mixing with PaATPPRT and PRPP (Figure 3.35, green
line). The steady state rate decreases, as expected by inhibition, to 7.56 ± 0.01 µM s−1
for this reaction. However, when histidine is preincubated with PaATPPRT and PRPP
before rapidly mixing with ATP (Figure 3.35, blue line), the amplitude of the burst phase
is reduced to 0.53 ± 0.01 µM despite the steady state rate of the inhibited reaction being
the same as before, at 7.83 ± 0.01 µM s−1. Since the histidine is all in one syringe, a small
lag phase due to mixing of histidine would be expected and is observed in the latter
condition. An additional control with the histidine distributed equally between both
syringes could be beneficial to confirm this effect. Taken together, these data implies
that the rate of ATP binding to the PaATPPRT:PRPP complex and product formation is
faster than histidine binding to the same complex and inhibition occurring. Since the
burst is significantly reduced when histidine is pre-incubated with the PaATPPRT:PRPP
complex, histidine must be able to bind to the binary complex. Furthermore, it must also
be able to form an inhibited complex in the absence of ATP since the burst amplitude
is considerably smaller and product release is therefore no longer rate limiting. In the
only other approach to steady state study carried out for an ATPPRT, M. tuberculosis
ATPPRT (which follows an ordered reaction with ATP binding first) the burst amplitude
decreased when ATP and histidine were rapidly mixed [58]. This contrasts with the
current findings for PaATPPRT. The error presented for experiments using the Stopped
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Flow spectrophotometer are from technical replicates only. Due to the large amount
of protein required, a biological replicate was not carried out specifically for each
experiment, although many batches of protein were used across the body of the work.
Each new batch of protein used was confirmed to have similar kcat and Km.
Figure 3.35: Rapid kinetics of histidine inhibition. Rapid mixing of ATP with PaATPPRT
and PRPP (red line), ATP and histidine with PaATPPRT and PRPP (green line), and ATP
with PaATPPRT, PRPP and histidine (blue line) Dashed lines are linear regression. Final
concentrations in the mixing chamber were 19 µM PaATPPRT, 0 or 30 µM histidine, 2
mM PRPP, 3.5 mM ATP.
3.4.5 Inhibition by Histidine does not Involve Release of Non-Activated
PaHisGS
Since PaHisGS has considerably reduced activity without PaHisZ, histidine’s mode of
inhibition on PaATPPRT could simply be to break apart the complex. This would release
free PaHisGS , which being insensitive to histidine, would be capable of utilising substrate
present in the assay and forming PRATP. If histidine were breaking up the PaATPPRT
complex to give free, non-activated PaHisGS , then the rate of PRATP formation of
inhibited PaATPPRT would be the same as the rate of PaHisGS alone. This can be tested
in a kinetics experiment but owing to the large discrepancy in enzyme concentration
required for PaHisGS activity compared to PaATPPRT, a conventional steady state assay
in a UV-VIS spectrophotometer and manual mixing would deviate from linearity too
soon. Therefore, a stopped flow spectrophotometer was used to catch the initial seconds
of the reaction, when PRATP formation is still linear even at relatively high enzyme
concentrations. When assayed, the rate of PRATP formation was lower for histidine
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inhibition of 2 µM PaATPPRT (purple) than for 2 µM PaHisGS (yellow) (Figure 3.36).
This was confirmed to be a statistically significant result by Student’s t-test with p <
0.0031. Therefore, histidine does not inhibit the complex merely by setting PaHisGS
free from the hetero-octamer. The rate of reaction upon histidine inhibition results in a
decrease in rate to that of between 1 µM and 2 µM PaHisGS activity alone and so histidine
must deregulate activity through a different mechanism.
Figure 3.36: Rapid kinetics of steady state histidine inhibition. (A) Time course of
PaHisGS and PaATPPRT reaction with and without 0.64 mM histidine. Lines are linear
regression. (B) Initial rates of PRATP formation extracted from (A). Inset is enlarged
view of (B). Final concentrations in the mixing chamber were 1 or 2 µM PaATPPRT or
PaHisGS , 0 or 640 µM histidine, 2 mM PRPP, 5.6 mM ATP.
The error presented for experiments using the Stopped Flow spectrophotometer are
from technical replicates only. Due to the large amount of protein required, a biological
replicate was not carried out specifically for each experiment, although many batches
of protein were used across the body of the work. Each new batch of protein used was
confirmed to have similar kcat and Km.
3.4.6 PaHisGS Mutant Sensitivity to Histidine in PaATPPRT Complex
Previous work from our lab [102], [101] show there is very little variation in structure
between PaHisGS and PaATPPRT despite the presence of PaHisZ leading to a large
activation of PaHisGS . There is an observed tightening of the overall PaHisGS dimer
upon PaHisZ binding which increases the cross-dimer contacts of some side chains, but
the most striking difference between PaATPPRT and PaHisGS lies in the deviations that
occur between the PRPP-, PRPP-ATP- and PRART-bound structures of PaATPPRT. The
position of Arg56 which is 12 A apart from the PRPP β-PO4 in the binary complex
shifts considerably to form a salt bridge with the PPi moiety of PRPP after the ternary
complex forms (Figure 3.37). This residue which traverses towards the active site only
upon ATP binding, sits in the middle of a flexible loop and is responsible for leaving
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group stabilisation at the transition state. Arg56 is highly conserved across the 18 species
of ATPPRT aligned in Alphey et. al. with only one species, T. maritima containing a
deletion at that site instead [101]. After the reaction has occurred, Arg56 moves again, to
reside 6 A away from its ternary complex location. This substantial movement of Arg56
is probably less favoured in PaHisGS , the non-activated form of the enzyme. Based on
structure, there is clear support for leaving group stabilisation as a key component of
PaHisGS activation by PaHisZ with the catalytically favoured position of Arg56 sampled
more often in PaATPPRT than in PaHisGS .
Figure 3.37: PaHisZ-induced active site preorganization in PaATPPRT: (A) overlay
of PRPP-ATP-bound PaATPPRT (magenta) and PaHisGS (gray) dimers; (B) active site
close-up of the superimposed dimers showing cross-subunit contacts. magnesium ions
are shown as green spheres, while substrates and Arg56 and Arg73 side chains are
represented as stick models with nitrogen in blue, oxygen in red, phosphorus in orange,
and carbon in magenta (PaATPPRT) and gray (PaHisGS ). Polar interactions are depicted
by dashed lines [101]
Previously [102], the R56A-PaHisGSmutant was shown to have 86-fold lower activity
than WT- PaHisGS , but only 6-fold less activity when in complex with PaHisZ. This
suggests that other conformations with leaving group stabilisation must still be sampled
without an Arg56 salt bridge. Additionally, the R56A-PaHisGS mutant complexed with
PaHisZ was proven, in this work, to retain histidine sensitivity (Figure 3.38). Hereby
excluding the Arg56 residue from a role in allosteric inhibition in addition to allosteric
activation.
As an additional area of interest in Ms Gemma Fisher’s work, she mutated C115 in
PaHisGS based on a hypothesis that it maybe acting as a general base during the PaHisGS
reaction. Unpublished data by Ms Fisher showed by NMR and steady state kinetics that
the C115S mutant lost all activity when PaHisGS is not activated, but regains full activity
when activated by PaHisZ (not shown). In this current work, the C115S mutant was
tested to determine if it was still sensitive to histidine. The C115S mutant did retain
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sensitivity to histidine (Figure 3.38) and is a puzzling area of ongoing investigation.
Figure 3.38: Sensitivity of WT PaHisGS (red), C115S-PaHisGS mutant (blue) and R56A-
PaHisGS (green) to 640 µM histidine. Presented on a logarithmic scale.
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3.5 Crystallographic Studies of PaATPPRT Inhibition by
Histidine
In order to fully understand the mode of allosteric inhibition of PaATPPRT by histidine,
a plausible crystal structure is sought. Based on the kinetic data suggesting that histidine
can bind to the binary and ternary complexes, both substrates were included in the
crystallisation.
3.5.1 Crystallisation Trials, X-ray Data Collection and Processing of
PaATPPRT:Histidine
Crystallisation conditions for PaATPPRT:ATP:PRPP:histidine were repeated as
previously published [101] using 11% PEG 3350, 0.1 M bicine (pH 8.5), 0.15 M
SrCl2, 0.15 M KBr, and 2% 1,6-hexanediol at 4 ◦C. PaHisGS and PaHisZ were mixed
in 1:1 molar ratio, and the buffer was exchanged with 0.02 M Tris (pH 7.0), 0.05 M
KCl, 0.01 M MgCl2, 2 mM DTT, 0.5 mM histidine, and 10 mM ATP. Repeating these
conditions yielded a few, small, cube-shaped crystals no larger than 0.05 × 0.05 × 0.03
mm3, as before, per batch. Despite histidine being present in the crystallisation buffer,
no histidine bound structure has ever been found with these conditions. ATP, PRPP and
histidine were soaked into the crystals.
Soaking trails of the crystal with substrate and histidine were carried out by soaking the
crystal in each of the substrates- and histidine- containing buffers for 3–60 min. From
the initial trial, only the fastest soaking (10 minutes Soaking Buffer 2 and 20 s Soaking
Buffer 3) diffracted successfully in-house. This crystal was retained, and further data
collected at the Diamond Light Source in order to improve resolution and data quality.
Initially, the successfully soaked crystal was processed as described in Section 2.7.3 at
2.63 A and space group P 1 211. Density corresponding to PRPP and histidine were
present with some partial density for adenine. However, although through repeated
rounds of refinement, the Rf actor = 0.200 and Rf ree = 0.282 were within acceptable limits,
the structure was plagued with numerous poor rotamers, strained bond angles and a
dubious amount of Ramachandran outliers (Figure 3.39). Additionally, there was not
enough density available in many of the side chains to pinpoint precisely their position.
To rectify this, side chains could be cut, but given the magnitude of the problem a
vast number would need to be removed, decreasing the overall quality of the output.
Therefore, the refinement of this crystal was abandoned at this point. Fortuitously, a
separate crystal from the same growth condition had been processed in parallel by our
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collaborator Dr Magnus Alphey. This crystal had similar setbacks when refining but
to a much lesser extent and the structure was fully resolved at 2.65 A. The structure
was deposited in the Protein Data Bank (PDB), entry 6R02. Table 3.2 outlines the
crystallographic parameters and statistics of the final structure. Going forward, these
data were used for all further analysis.
Figure 3.39: Molprobity output after multiple rounds of refinement for the initial crystal
processed. Red indicates the required standard has not been achieved. Green indicates
the value obtained conforms to the required standard. Yellow indicates borderline
agreement with the required standard.[145]
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Table 3.2: Crystallographic data and refinement statistics for PaATPPRT:PRPP:histidine
.
PDB entry 6R02
Structure PaHisGSZ + histidine + PRPP
Beamline I24
Wavelength ( A) 0.9686
Resolution ( A) 77.31 – 2.65
Space group P21
No. molecules in a.u. 4 PaHisZ + 4 PaHisGS
Total No. reflections 254279
No. unique reflections 75715
Multiplicity 3.4 (3.4)




Wilson B ( A2) 60.6
Unit cell parameters
a ( A) 93.3
b ( A) 147.3





No. reflections (working set) 71962
No. reflections (Rf ree test set) 3726
Rwork/Rf reeb/c 0.24 / 0.27
r.m.s.d bond distances ( A) 0.004
r.m.s.d. bond angles (°) 1.286
Protein atoms 17880
Ligands (histidine+PRPP) 4 + 4
Waters 54
Average B factor ( A2)
Protein 85.6







|I(hkl ) – I| × 100/
∑
|I(hkl )|, where the average intensity I is taken over all symmetry
equivalent measurements and I(hkl ) is the measured intensity for a given observation. bRwork =∑
hkl ||Fo(hkl)| – |Fc(hkl)||/
∑
hkl |Fo(hkl)|. cRf ree = Rf actor for a test-set of reflections (5%).
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Analysis of the PaATPPRT:PRPP:histidine crystal structure.
3.5.2 Histidine Binds in the Site Conserved in HisRS
The PaATPPRT:PRPP:histidine structure crystallised in the P21space group with the
entire hetero-octameric complex within the asymmetric unit. As with the previous
PaATPPRT structures [20, 101, 102], PaHisZ subunits sit crossed in the middle of
the octameric complex with PaHisGS dimers flanking top and bottom (Figure 3.40A).
Density corresponding to PRPP was found in all four PaHisGS binding sites as in
previous structures [101]. When PRPP is bound to PaATPPRT the substrate is secured to
the active site via main and side chain interactions between the PRPP binding loop and
the phosphate of PRPP. There is also a hydrogen bond (H-bond) between the substrate
2-OH group and side chain residue Asp176 that stops PRPP from blocking the ATP
binding site. This is similar to the PRPP bound structure of L. lactis [70] and PaHisGS
alone, but not C. jejuni [86].
Figure 3.40: Crystal structure of PaATPPRT:PRPP:histidine. (A) Ribbon diagram of the
PaATPPRT hetero-octamer found in the asymmetric unit. (B) Omit map showing electron
density for histidine. (C) Ribbon diagram of the PaHisZ subunit with the location of the
bound histidine. PaHisGS subunits are in cyan, PaHisZ in yellow. Ligands are shown in
stick models with carbon atoms matching the colour of the subunits to which they are
bound.
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Here, for the first time, clear electron density for a histidine molecule (Figure 3.40 B) has
been reported in the binding site analogous to HisRS, along the central antiparallel β-
sheet of each molecule of PaHisZ (Figure 3.40C). No density for histidine was found at the
interface of PaHisGS and PaHisZ subunits, contradicting the only previously published
structure of a short-form ATPPRT:histidine complex (T. maritima) which depicted two
histidine binding sites at the catalytic and regulatory sub-unit interface [84]. However,
this interface resides over 18 A away from the histidine binding site occupied in the
PaATPPRT structure. Figure 3.42 highlights the discrepancy with the T. maritima
binding sites (blue boxes) but the striking agreement with the histidine binding site of
Burkholderia thailandensis HisRS (red box). Given that HisZ and HisRS share a common
protein ancestor, this finding is reasonable and confirms previous speculation [70].
Figure 3.41: Overlay of histidine-bound PaHisZ, T. maritima HisZ, and B. thailandensis
HisRS structures. Histidine molecules are shown in stick models. T. maritima histidine
binding sites are highlighted with blue boxes and the PaHisZ and B. thailandensis HisRS
histidine binding sites are shown in a red box.
3.5.3 The Histidine Binding Site
Histidine is held within the PaHisZ binding site by an extensive array of polar
interactions to protein side chain residues (Figure 3.42). The α-COO- group of histidine
contacts the δ-NH and ω-NH2 groups of Arg284 and the γ-NH2 group of Gln118.
Histidine α-NH2 interacts via hydrogen bonds with Tyr265 4-OH group and Ser308 and
Thr78 β-OH groups, and via a salt-bridge with Asp76 β-COO- group. The imidazole
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ring of the inhibitor is anchored to the β-strand via an interaction between its τ-NH
and Glu122 γ-COO-, and has further contact with a flexible loop that also includes
Tyr265 via an interaction between its π-N and His266 τ-NH. Given that histidine is an
allosteric inhibitor of PaATPPRT and TIH is not, these imidazole interactions may be of
vital importance to the mode of allosteric inhibition since in their absence, no inhibition
occurs.
Figure 3.42: Enlarged view of the histidine binding site in PaHisZ. The figure shows
histidine and relevant side chains in stick models, carbon (yellow), nitrogen atoms (blue),
oxygen atoms (red), protein backbone (ribbon diagram) and polar contacts depicted by
dashed lines.
3.5.4 Structural Basis of PaATPPRT Inhibition and Consequences of
Allosteric Regulation
The allosteric activation of PaHisGS by PaHisZ (where the dimer contracts, allowing the
PaHisGS loop movement and stabilisation of the leaving group transition state), only
occurs after ATP binding [102]. Therefore, the PaATPPRT:PRPP complex is in a non-
activated state. When the structure of PaATPPRT:PRPP:histidine is overlaid with this
structure the Cα root-mean-square deviations (rmsd) was 0.40 rmsd (Figure 3.43A).
Similarly, when the PaHisZ tetramers are overlaid the rsmd is 0.38 (Figure 3.43B)
and the PaHisGS dimers have rmsd of 0.27 (Figure 3.43C). The overlaid structures of
PaATPPRT:PRPP:ATP and PaATPPRT:PRPP:histidine on the other hand have rmsd of
1.71, 1.37 and 1.75 respectively for the hetero-octamer, PaHisZ tetramer and PaHisGS
dimers. Clearly, PaATPPRT:PRPP:histidine is not in the activated form and is similar in
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structure to the non-activated conformation (when ATP is not bound). Perhaps, histidine
locks PaATPPRT in this non-activated form, preventing conformational changes that
would subsequently occur upon ATP binding.
Figure 3.43: Overlay of PaATPPRT:PRPP, PaATPPRT:PRPP:histidine, and
PaATPPRT:PRPP:ATP structures. (A) full hetero-octamers, (B) PaHisZ tetramers
and (C) PaHisGSdimers.
When the PaHisZ subunits from all published structures: PaATPPRT
[20], PaATPPRT:PRPP, PaATPPRT:PRPP-ATP, PaATPPRT:PRATP [101] and
PaATPPRT:PRPP:histidine Cα atoms are overlaid (Figure 3.44) two loops are seen
to move substantially (shown by black arrows in Figure 3.44A) whereas the rest of
the PaHisZ structures vary very little from one the another. These loops (labelled as
in the PaATPPRT:PRPP:histidine complex), span from Asp256 – Ile269 (the histidine
binding loop) and from Asp101 - Leu117 at the PaHisZ/PaHisGS interface. The latter
loop (Asp101 – Leu117) differs by over 2 A in the PaATPPRT:PRPP:ATP activated
conformation (Figure 3.44, grey) compared to all the other published PaATPPRT
structures (Figure 3.44B, right), which are non-activated. The former loop (Asp256-
Ile269) differs by over 4.5 A between the PaATPPRT:PRPP:histidine structure (Figure
3.44, yellow) and all other published structures (Figure 3.44B, left). This includes an
alternative His266 rotamer (for interaction with histidine (Figure 3.42) and a 4 A shift
of Tyr265 to form a hydrogen bond with the inhibitor. This results in the Tyr265 4-OH
group residing 6 A away (Figure 3.44B, yellow) from its position in all other structures.
In the PaATPPRT:PRPP:histidine structure, these two loops are connected by a hydrogen
bond between Tyr263 (histidine binding loop) and His104 (Asp101-Leu117 at the
PaHisZ/PaHisGS interface). This connection, which requires the tyrosine to rotate
almost 180° from its most common position, is not seen in any of the other PaATPPRT
structures.
When PaATPPRT:PRPP:histidine (an unactivated form) and PaATPPRT:PRPP:ATP
(activated form) are overlaid (Figure 3.45) the activated form’s Asp101-Leu117 interface
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Figure 3.44: Overlay of PaHisZ subunit conformations of all PaATPPRT structures. (A)
Overlay of PaHisZ subunits from all PaATPPRT structures (black arrows show the two
loops with substantial movement) and (B) enlarged view of the two loops subject to large
spatial movement. PaHisZ residue side chains and bound histidine are shown in stick
models and dashed lines show polar interactions. Black arrows highlight the different
positions adopted by the same residue side chains in the different structures.
loop has residues Leu110 and Phe111 ideally positioned for hydrophobic interaction
with the PaHisGSmonomer. Whereas in the inhibited structure, this loop is positioned
towards the other PaHisGSmonomer which situates Leu110 in a position capable of
disrupting its Glu82-His103 interaction. In addition, the inhibited structure also sees the
aromatic ring of Phe111 shift closer to the interface between the two PaHisGS subunits
further disrupting the hydrophobic interactions made here, in the activated complex.
These interactions likely prevent the efficient sampling by the Asp101–Leu117
loop of the conformation that triggers catalytic activation when ATP binds to the
PaATPPRT:PRPP complex in the absence of histidine. Perhaps it is also these changes in
the interactions between the PaHisZ loop and PaHisGS monomers that are responsible, at
least in part, for transmitting the allosteric signal from the regulatory subunit (PaHisZ) to
the active site in the catalytic subunit (PaHisGS ). Nevertheless, the binding of inhibitor
in PaHisZ directly causes a shift of the α-helix and β-strand which connects the loop
responsible for cross-subunit stabilisation of leaving group departure near the active site
in PaHisGS , further from where the adjacent catalytic subunit resides in the activated
form (Figure 3.45, black arrows). Taken together, these differences between the activated
form of PaATPPRT:PRPP:ATP and the PaATPPRT:PRPP:histidine structures clearly
demonstrate structural changes that are directly due to allosteric binding. Consequently,
in the case of PaATPPRT, allosteric binding reduces the likelihood of sampling the
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activated conformation upon ATP binding, thus stochastically restricting the structure
to a non-activated form.
Figure 3.45: Ribbon diagram of overlaid PaATPPRT:PRPP:histidine and
PaATPPRT:PRPP:ATP structures detailing part of one PaHisZ and one of the
PaHisGSdimers at the PaHisZ-PaHisGSand PaHisGS-PaHisGS interfaces. The figure
shows substrates as wire frame, histidine and relevant side chains in stick models
(carbon corresponding to subunit ribbon colour), nitrogen atoms (blue), oxygen atoms
(red), protein backbone (ribbon diagram). Black arrows denote the distinct positions of





This work demonstrates the first example of histidine binding in a site analogous to
that of HisRS in a short-form ATPPRT. The resulting interaction between two loops in
PaHisZ mediated by a hydrogen bond between Tyr263 and His104 is likely to greatly
reduce the probability of the complex sampling the activated conformation necessary
for successful reaction despite the ability of histidine to bind to the free enzyme, the
PaATPPRT:PRPP bound state and the PaATPPRT:PRPP:ATP bound state. Additionally,
this work highlights a clear distinction between the activated form with ATP bound and
all other structures. Although the ATP bound structure previously published shows ATP
bound in a non-catalytically competent conformation (which could influence enzyme
dynamics) the majority, if not all, of the interactions established are likely to still be
present in the catalytic rotamer. Overall, this work demonstrates a clear reliance on
structural changes for the allosteric regulation of PaATPPRT.
Although clear, the changes observed are not dramatic and this may be due to the
restriction of movement imposed by crystal packing and the potentially limiting nature
of exposing the crystal to histidine by soaking. It may be that the effects detailed here
are more pronounced in solution but selected key mutations of Tyr265, Tyr263, Leu110
and Phe111 will highlight the importance of the interactions theorised here. Of these
mutations, Tyr265Phe is currently underway within the da Silva group to determine
whether removal of this interaction interrupts transmission of the allosteric signal and
renders the enzyme insensitive to histidine inhibition. If successful, this gives scope for
biotechnological advancement and drug discovery. Since P. arcticus and A. baumannii
both contain a short-form ATPPRT (with 43% sequence alignment for HisZ and 69%
for HisG), confirming the importance of the residues involved in binding and allosteric
signal relay in PaATPPRT may provide insight into ways to design allosteric modulators
104
of A. baumannii ATPPRT for antibiotic development. Furthermore, creating a mutant
of PaATPPRT capable of histidine production insensitive to feedback inhibition but still
profiting from the activation of PaHisGS by PaHisZ has clear advantages for industrial
histidine production. In addition, this work has confirmed ADP as a viable alternative
substrate for PaATPPRT, with no indication of substrate inhibition, which complements
this biosynthesis strategy.
Overall, this work provides the most detailed account of the allosteric inhibition
mechanism of a short-form ATPPRT.
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